UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~October~~April 3130, ~~2024~~2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File Number ~~001~~000-~~40854~~55654

NUTRIBAND INC.

(Exact name of registrant as specified in its charter)

NEVADA		81-1118176
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

121 South Orange Ave., Suite 1500, Orlando, FL		32801
(Address of Principal Executive Offices)		(Zip Code)

(407) 377-6695

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	NTRB	The Nasdaq Stock Market LLC
Warrants	NTRBW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☐☒ No ☒☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares outstanding of the issuer’s common stock, par value $0.001 per share, was 11,~~106~~154,~~185~~171 shares as of ~~December~~May 230, ~~2024~~2025.

NUTRIBAND INC.

INDEX

		Page No.
Part I: Financial Information		1
Item 1	Financial Statements	1
	Condensed Consolidated Balance Sheets as of October 31, 2024 (unaudited) and January 31, 2024.	2
	Condensed Consolidated Balance Sheets as of April 30, 2025 (unaudited) and January 31, 2025.	2
	Condensed Consolidated Statements of Operations for the three and nine months ended October 31, 2024 and 2023(unaudited),	3
	Condensed Consolidated Statements of Operations for the three months ended April 30, 2025 and 2024 (unaudited),	3
	Consolidated Statements of Stockholders’ Equity for the nine months ended October 31, 2024, and 2023 (unaudited)	4
	Consolidated Statements of Stockholders’ Equity for the three months ended April 30, 2025 and 2024 (unaudited)	4
	Condensed Consolidated Statements of Cash Flows for the three and nine months ended October 31, 2024, and 2023 (unaudited)	6
	Condensed Consolidated Statements of Cash Flows for the three months ended April 30, 2025, and 2024 (unaudited)	5
	Notes to Unaudited Condensed Consolidated Financial Statements	76
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2522
Item 3	Quantitative and Qualitative Disclosures about Market Risk	3430
Item 4	Controls and Procedures	3430
Part II: Other Information		3531
Item 1.	Legal Proceedings	3531
Item 1A	Risk Factors	3531
Item 6	Exhibits	3932

NUTRIBAND INC.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Certain information and footnote disclosures required under accounting principles generally accepted in the United States of America have been condensed or omitted from the following financial statements pursuant to the rules and regulations of the Securities and Exchange Commission.

The results of operations for the three ~~and nine~~ months ended ~~October~~April 3130, ~~2024~~2025, and ~~2023~~2024 are not necessarily indicative of the results for the entire fiscal year or for any other period.

NUTRIBAND INC. AND SUBSIDIARIES

~~CONDENSED~~ CONSOLIDATED BALANCE SHEETS

	October 31,			January 31,
		April 30,			January 31,
	2024			2024
		2025			2025
ASSETS	(Unaudited)
		(Unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	52,~~698~~964,~~187~~097		$	~~492~~4,~~942~~311,719
Accounts receivable		109,630			148,649
Accounts receivable-net		94,136			73,847
Inventory		~~168~~215,~~299~~324			~~168~~212,~~605~~041
Prepaid expenses		~~215~~156,~~486~~090			~~211~~196,~~667~~658
Total Current Assets		63,~~191~~429,~~602~~647			14,~~021~~794,~~863~~265
PROPERTY & EQUIPMENT-net		~~739~~658,~~630~~073			~~774~~695,~~924~~063
OTHER ASSETS:
Goodwill		51,~~021~~719,~~713~~535			51,~~021~~719,~~713~~535
Operating lease right of use asset		799,~~839~~000			~~31,374~~-
Intangible assets-net		~~582~~245,~~418~~926			~~667~~261,~~280~~092
TOTAL ASSETS	$	126,~~543~~152,~~202~~181		$	7,~~517~~469,~~154~~955
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	~~892~~721,~~154~~671		$	~~680~~698,~~132~~821
Deferred revenue		~~218~~44,~~868~~680			~~157~~155,~~502~~880
Operating lease liability-current portion		830,~~864~~309			~~34,276~~-
Notes payable-current portion		~~127~~128,~~900~~391			~~127~~128,~~183~~144
Total Current Liabilities		1925,~~247,786~~051			~~999~~982,~~093~~845
LONG-TERM LIABILITIES:
Note payable-net of current portion		6352,~~717~~632			7958,~~826~~205
Total Liabilities		1,311,503			1,078,919
Operating lease liability-net of current portion		71,112			-
Total Liabilities		1,048,795			1,041,050
Commitments and Contingencies		-			-
STOCKHOLDERS’ EQUITY:
Preferred stock, $.001 par value, 10,000,000 shares authorized, -0- outstanding		-			-
Common stock, $.001 par value, 291,666,666 shares authorized; 11,106,185 and 8,869,870 shares issued at October 31, 2024 and January 31,2024, respectively, 11,106,105 and 8,859,870 shares outstanding as of October 31, 2024 and January 31, 2024, resectively		11,106			8,860
Common stock, $.001 par value, 291,666,666 shares authorized, 11,154,171 and 11,107,210 shares issued at April 30, 2025 and January 31, 2025, respectively, 11,130,271 and 11,074,810 shares outstanding as of April 30, 2025 and January 31, 2025, respectively		11,130			11,075
Additional paid-in-capital		4445,~~167~~053,~~095~~767			3445,~~442~~029,~~339~~317
Accumulated other comprehensive loss		(304	)		(304	)
Treasury stock, -0- and 10,000 shares at cost, respectively		-			(32,641	)
Treasury stock, 23,900 and 32,400 shares at cost, as of April 30, 2025 and January 31, 2025, respectively		(109,702	)		(148,547	)
Accumulated deficit		(3239,~~946~~851,~~198~~505	)		(2738,~~980~~462,~~019~~636	)
Total Stockholders’ Equity		115,~~231~~103,~~699~~386			6,~~438~~428,~~235~~905
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	126,~~543~~152,~~202~~181		$	7,~~517~~469,~~154~~955

See notes to unaudited consolidated financial statements

NUTRIBAND INC. AND SUBSIDIARIES

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

	For the Three Months Ended						~~For the Nine Months Ended~~
	October 31,						October 31,
	April 30,
	2024			2023			2024			2023
	2025			2024
Revenue	$	~~645~~667,~~796~~432		$	~~427~~408,~~841~~532		$	~~1,497,158~~		$	~~1,560,701~~
Costs and expenses:
Cost of revenues		~~454~~415,~~767~~451			~~268~~243,~~920~~746			~~1,039,785~~			~~879,824~~
Research and development		~~880~~683,~~768~~426			~~551~~974,~~503~~535			~~2,629,278~~			~~1,397,055~~
Selling, general and administrative		~~737~~982,~~102~~052			1,~~330~~079,~~929~~728			~~2,554,155~~			~~2,849,399~~
Total Costs and Expenses		2,~~072~~080,~~637~~929			2,~~151~~298,~~352~~009			~~6,223,218~~			~~5,126,278~~
Loss from operations		(1,~~426~~413,~~841~~497	)		(1,~~723~~889,~~511~~477	)		~~(4,726,060~~	)		~~(3,565,577~~	)
Other income (expense):
Interest income		6830,~~235~~508			~~3,765~~18			~~145,585~~			~~13,830~~
Loss on extinguishment of debt		-						(368,036	)
Interest expense		(5,880	)		(8,618	)
Interest expense		(4,031	)		(40,200	)		(17,668	)		(52,601	)
Total other income (expense)		24,628			(8,600	)
Total other income (expense)		64,204			(36,435	)		(240,119	)		(38,771	)
Loss before provision for income taxes		(1,388,869	)		(1,898,077	)
Loss before provision for income taxes		(1,362,637	)		(1,759,946	)		(4,966,179	)		(3,604,348	)
Provision for income taxes		-			-
Provision for income taxes		-			-			-			-
Net loss	$	(1,388,869	)	$	(1,898,077	)
Net loss	$	(1,362,637	)	$	(1,759,946	)	$	(4,966,179	)	$	(3,604,348	)
Net loss per share of common stock-basic and diluted	$	(0.12	)	$	(0.21	)
Net loss per share of common stock-basic and diluted	$	(0.12	)	$	(0.22	)	$	(0.48	)	$	(0.46	)
Weighted average common shares outstanding
Weighted average shares of common stock outstanding - basic and diluted		11,101,945			7,833,150			10,441,501			7,833,150
- basic and diluted		11,125,800			9,159,869

See notes to unaudited consolidated financial statements

NUTRIBAND INC. AND SUBSIDIARIES

~~UNAUDITED~~ CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

Nine Months Ended October 31, 2024
											Accumulated
				Common Stock				Additional			Other
				Number of				Paid In			Comprehensive			Accumulated			Treasury
	Total			shares		Amount		Capital			Income (Loss)			Deficit			Stock
Balance, February 1, 2024	$	6,438,235			8,859,870	$	8,860	$	34,442,339		$	(304	)	$	(27,980,019	)	$	(32,641	)
Options issued for services		553,335			-		-		553,335			-			-			-
Proceeds from sale of common stock and warrants		8,400,000			2,100,000		2,100		8,397,900			-			-			-
Common stock and warrants issued for conversion of debt		672,958			76,230		76		672,882
Treasury stock and warrants issued for services		133,350			10,000		10		100,699									32,641
Cashless exercise of warrants		-			60,085		60		(60	)
Net loss for the nine months ended October 31, 2024		(4,966,179	)		-		-		-			-			(4,966,179	)		-
Balance, October 31, 2024	$	11,231,699			11,106,185	$	11,106	$	44,167,095		$	(304	)	$	(32,946,198	)	$	-

Three Months Ended April 30, 2025

Six Months Ended July 31, 2023
											Accumulated
				Common Stock				Additional			Other
				Number of				Paid In			Comprehensive			Accumulated			Treasury
	Total			shares		Amount		Capital			Income (Loss)			Deficit			Stock
Balance, February 1, 2023	$	8,572,990			7,833,150	$	7,833	$	31,092,807		$	(304	)	$	(22,494,705	)	$	(32,641	)
Balance, February 1, 2025	$	6,428,905			11,074,810	$	11,075	$	45,029,317		$	(304	)	$	(38,462,636	)	$	(148,547	)
Warrants issued for services		242,840			-		-		242,840			-			-			-
Treasury stock issued for services		63,350			8,500		9		24,496			-			-			38,845
Options issued for services		499,856			-		-		499,856			-			-			-
Cashless exercise of warrants		-			46,961		46		(46	)		-			-			-
Net loss for the nine months ended October 31, 2023		(3,604,348	)		-		-		-			-			(3,604,348	)		-
Net loss		(1,388,869	)		-		-		-			-			(1,388,869	)		-
Balance, October 31, 2023	$	5,711,338			7,833,150	$	7,833	$	31,835,503		$	(304	)	$	(26,099,053	)	$	(32,641	)
Balance, April 30, 2025	$	5,103,386			11,130,271	$	11,130	$	45,053,767		$	(304	)	$	(39,851,505	)	$	(109,702	)

4Three Months Ended April 30, 2024

Three Months Ended October 31, 2024
										Accumulated
				Common Stock				Additional		Other
				Number of				Paid In		Comprehensive			Accumulated			Treasury
	Total			shares		Amount		Capital		Income (Loss)			Deficit			Stock
Balance, August 1, 2024	$	12,460,986			11,096,185	$	11,096	$	44,066,396	$	(304	)	$	(31,583,561	)	$	(32,641	)
Balance, February 1, 2024	$	6,438,235			8,859,870	$	8,860	$	34,442,339	$	(304	)	$	(27,980,019	)	$	(32,641	)
Treasury stock and warrants issued for services		133,350			10,000		10		100,699		-			-			32,641
Proceeds from sale of common stock and warrants		8,400,000			2,100,000		2,100		8,397,900		-			-			-
Net loss for the three months ended October 31, 2024		(1,362,637	)		-		-		-		-			(1,362,637	)		-
Options issued for services		422,955			-		-		422,955		-			-			-
Balance, October 31, 2024	$	11,231,699			11,106,185	$	11,106	$	44,167,095	$	(304	)	$	(32,946,198	)	$	-
Net loss		(1,898,077	)		-		-		-		-			(1,898,077	)		-
Balance, April 30, 2024	$	13,363,113			10,959,870	$	10,960	$	43,263,194	$	(304	)	$	(29,878,096	)	$	(32,641	)

Three Months Ended October 31, 2023
										Accumulated
				Common Stock				Additional		Other
				Number of				Paid In		Comprehensive			Accumulated			Treasury
	Total			shares		Amount		Capital		Income (Loss)			Deficit			Stock
Balance, August 1, 2023	$	6,890,708			7,833,150	$	7,833	$	31,254,927	$	(304	)	$	(24,339,107	)	$	(32,641	)
Warrants issued for services		155,750			-		-		155,750		-			-			-
Options issued for services		424,826			-		-		424,826		-			-			-
Net loss for the three months ended October 31, 2023		(1,759,946	)		-		-		-		-			(1,759,946	)		-
Balance, October 31, 2023	$	5,711,338			7,833,150	$	7,833	$	31,835,503	$	(304	)	$	(26,099,053	)	$	(32,641	)

See notes to unaudited consolidated financial statements

NUTRIBAND INC. AND SUBSIDIARIES

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the Nine Months Ended
	For the Three Months Ended
	October 31,
	April 30,
	2024			2023
	2025			2024
Cash flows from operating activities:
Net loss	$	(41,~~966~~388,~~179~~869	)	$	(31,~~604~~898,~~348~~077	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		~~212~~57,~~199~~480			~~218~~69,~~382~~101
Operating lease expense		239,~~535~~000			237,~~535~~845
Reserve for doubtful accounts		-			11,837
Stock-based compensation-shares issued for services		63,350			-
Loss on extinguishment of debt		368,036			-
Stock-based compensation-options		-			422,955
Treasury stock and warrants issued for services		133,350			242,840
Stock-based compensation-options		553,335			499,856
Changes in operating assets and liabilities:
Accounts receivable		39(20,~~019~~289	)		~~(68~~63,~~461~~505	)
Prepaid expenses		(340,~~819~~568	)		~~(24~~84,~~179~~631	)
Inventories		~~306~~(3,283	)		54(1,~~694~~415	)
Deferred revenue		61(111,~~366~~200	)		6111,~~592~~843
Operating lease liability		(256,~~412~~579	)		(238,~~200~~288	)
Accounts payable and accrued expenses		~~216~~22,~~944~~850			~~(146~~313,~~817~~974	)
Net Cash Used In Operating Activities		(31,~~387~~336,~~320~~972	)		(2833,~~809,269~~926	)
Cash flows from investing activities:
Purchase of equipment		(925,~~043~~324	)		(26,~~624~~195	)
Net Cash Used in Investing Activities		(925,~~043~~324	)		(26,~~624~~195	)
Cash flows from financing activities:
Proceeds from note payable-related party		~~300,000~~-			2300,000~~,000~~
Proceeds from secured loan liability		-			106,528
Proceeds from sale of common stock and exercise of warrants		-			8,400,000
Proceeds from sale of common stock and warrants		8,400,000			-
Payment on note payable		(5,326	)		(5,081	)
Payment on note payable		(15,392	)		(14,752	)
Net Cash Provided by Financing Activities		(5,326	)		8,694,919
Net Cash Provided by Financing Activities		8,684,608			2,091,776
Net change in cash		(1,347,622	)		7,854,798
Net change in cash		5,205,245			(720,117	)
Cash and cash equivalents - Beginning of period		4,311,719			492,942
Cash and cash equivalents - Beginning of period		492,942			1,985,440
Cash and cash equivalents - End of period	$	2,964,097		$	8,347,740
Cash and cash equivalents - End of period	$	5,698,187		$	1,265,323
Supplementary information:
Cash paid for:
Interest	$	~~611~~621		$	~~7,352~~611
Income taxes	$	~~2,043~~-		$	-
Supplemental disclosure of non-cash investing and financing activities:
Debt settlement issued by the issuance of common stock and warrants	$	672,958		$	-
Cashless conversion of warrant	$	46		$	-
Cashless exercise of warrants	$	60		$	-
Measurement of Operating Lease Right-of-Use Assets and Liabilities	$	108,000		$	-

See notes to unaudited consolidated financial statements

NUTRIBAND INC. AND SUBSIDIARIES

Notes to Unaudited Consolidated Financial Statements

as of and for the ~~Nine~~Three Months Ended ~~October~~April 3130, ~~2024~~2025 and ~~2023~~2024

1.	ORGANIZATION AND DESCRIPTION OF BUSINESS

Organization

Nutriband Inc. (the “Company”) is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd, an Irish company which was formed by the Company’s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches. References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise.

On August 1, 2018, the Company acquired 4P Therapeutics LLC (“4P Therapeutics”) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000, and $400,000, and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics was a director of the Company from April 2018, when the Company entered into an agreement to acquire 4P Therapeutics until ~~they~~he resigned as a director in January 2022.

4P Therapeutics is engaged in the development of transdermal pharmaceutical products. With the acquisition of 4P Therapeutics, 4P Therapeutics’ drug development business became the Company’s principal business. The primary focus of the business is to incorporate the Company’s Aversa abuse deterrent technology into transdermal patches containing already approved drugs. Although these drugs are already approved, the Company needs to conduct a product development program which will include the preclinical and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical products.

On August 25, 2020, the Company formed Pocono Pharmaceuticals Inc. (“Pocono Pharmaceuticals”), a wholly owned subsidiary of the Company. On August 31, 2020, the Company acquired certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical ~~business~~businesses of Pocono Coated Products LLC (“PCP”). The net assets were contributed to Pocono Pharmaceuticals. Included in the transaction, Pocono Pharmaceuticals also acquired 100% of the membership interests of Active Intelligence LLC (“Active Intelligence”).

Pocono Pharmaceuticals is a coated products contract development and manufacturing organization that supports their customers with product design, development and manufacturing services. Pocono Pharmaceuticals has specialized expertise and state-of-the-art manufacturing capabilities for topical, transdermal and kinesiology tape products. Active Intelligence manufactures activated kinesiology tape for customers in the sports and physical markets.

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Unaudited Financial Statements

The consolidated balance sheet as of ~~October~~April 3130, ~~2024~~2025, and the consolidated statements of operations, stockholders’ equity, and cash flows for the periods presented have been prepared by the Company and are unaudited. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) ~~necessary~~ to prepare fairly the financial position, results of operations, changes in stockholders’ equity and cash flows for all periods presented have been made. The results for the ~~nine~~three months ~~ended~~ending ~~October~~April 3130, ~~2024~~2025, are not necessarily indicative of the results to be expected for the full year. The consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes therein ~~thereto~~ included in Nutriband’s Annual Report on Form 10-K for the year ~~ended~~ending January 31, ~~2024~~2025.

Certain ~~information~~ information and footnote disclosures required under generally accepted accounting principles in the United States of America (U.S. GAAP”) have been condensed or omitted from these consolidated financial statements pursuant to the rules and regulations, including interim reporting requirements of the U.S. Securities and Exchange Commission (“SEC”). The preparation of consolidated ~~financial statements~~ statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and the disclosures of contingent amounts in our consolidated financial statements and accompanying footnotes. Actual results could differ from estimates.

The Company’s significant accounting policies are in Note 2 in the Company’s Annual Report on Form 10-K for the year ~~ended~~ending January 31, ~~2024~~2025. ~~There~~ There were no significant changes to these accounting policies during the ~~nine~~three months ~~ended~~ending ~~October~~April 3130, ~~2024~~2025.

Going Concern Assessment

Management assesses liquidity and going concern uncertainty in the Company’s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the “look-forward period”, as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved, and management has the proper authority to execute them within the look-forward period.

As of ~~October~~April 3130, ~~2024~~2025, the Company had cash and cash equivalents of $52,~~698~~964,~~187~~097 and working capital of $42,~~934~~504,~~816~~596. For the ~~nine~~three months ~~ended~~ending ~~October~~April 3130, ~~2024~~2025, the Company incurred a net loss from operations of $41,~~726~~413,~~060~~497 and used cash flow from operations of $31,~~387~~336,~~320~~972. The Company has generated operating losses since its inception and has relied on sales of securities and the issuance of third-party and related-party debt to support cash flow from operations. The Company has used these proceeds to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three-year $2,000,000 Credit Line Note facility with a related party, amended on July 13, 2023, to $5,000,000, which will permit the Company to draw down on the credit line to fund the Company’s research and development of its Aversa product. On April 19, 2024, the Company received proceeds of $8,400,000 from equity financing with European investors.

Management has prepared estimates offor operations for the next twelve months and believes that sufficient funds will be generated from operations to to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates ~~improved~~ improved operations and the Company’s ability to continue operations as a going concern.

Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.

Principles of Consolidation

The consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company’s financial statements from the date of acquisition of August 1, 2018, and the acquired operations of Pocono Coated Products and Active Intelligence are included in the Company’s financial statements from the date of acquisition of September 1, 2020, under Pocono Pharmaceuticals Inc. The wholly owned subsidiaries are as follows:

Nutriband Ltd.

4P Therapeutics LLC

Pocono Pharmaceuticals Inc.

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

Revenue Recognition

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.

Revenue Types

The following is a description of the Company’s revenue types, which include professional services and sale of goods:

●

Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods.

●

Product revenues derived from the sale of the Company’s consumer transdermal, topical and tape products with sales listed under sale of goods.

● Contract research and development services for pharmaceutical and medical ~~devices~~device ~~for~~ life sciences customers with revenues listed under services.

Contracts with Customers

A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.

Contract Liabilities

Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

Performance Obligations

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of ~~account~~accounts in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue service types, the performance obligation is satisfied at different times. The Company’s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month.

All revenue recognized in the income statement is considered to be revenue from contracts with customers.

Disaggregation of Revenues

The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables:

	Nine Months Ended				Three Months Ended
	Three Months Ended
	October 31,				October 31,
	April 30,
	2024		2023		2024		2023
	2025		2024
Revenue by type
Sale of goods	$	1667,~~497,158~~432	$	1408,~~395,667~~532	$	~~645,796~~	$	~~427,841~~
Services		-		~~165,034~~-		-		-
Total	$	1667,~~497,158~~432	$	1408,~~560,701~~532	$	~~645,796~~	$	~~427,841~~

	Nine Months Ended				Three Months Ended
		Three Months Ended
	October 31,				October 31,
		April 30,
	2024		2023		2024		2023
		2025		2024
Revenue by geographic location:	$	~~1,497,158~~	$	~~1,560,701~~	$	~~645,796~~	$	~~427,841~~
United States	$	-667,432	$	-408,532		-		-
Foreign	$	~~1,497,158~~-	$	~~1,560,701~~-	$	~~645,796~~	$	~~427,841~~
	$	667,432	$	408,532

Cash and cash equivalents.

Cash and cash equivalents include cash on hand, and cash on deposit in money market accounts. The Company considers short-term highly liquid investments with an original ~~maturity~~ maturity date of three months or less that are not part of an investment pool to be cash equivalents. As of ~~October~~April 3130, ~~2024~~2025, the Company had $52,~~171~~547,000 that exceeded federally insured cash balance limits.

Accounts receivable

Trade accounts receivables are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make the required payments. The Company determines its allowances by both ~~specific~~ specific identification of customer accounts where appropriate and the application of historical loss to non-applicable accounts. For the ~~nine~~ three months ~~ended~~ending ~~October~~April 3130, ~~2024~~2025, and ~~2023~~2024, the Company recorded bad debt expenses of $~~1,200~~-0- and $111,~~836~~200, respectively, for doubtful ~~accounts~~ accounts related to accounts receivable. During the year ended January 31, 2024, the Company entered into an accounts receivable sale ~~agreement~~ agreement for one of its subsidiaries. The Company received $106,528 in funds against an account receivable that is currently a claim in bankruptcy. The net accounts receivable ~~remain~~remains on the books of the Company and a corresponding amount has been included as a secured borrowing liability under Notes payable. As of ~~October~~April 3130, ~~2024~~2025, the receivable has been reserved in full. If the bankruptcy claim is not paid in full by the debtor, Company is obligated to pay any difference to the factor. The loan bears interest at 10%. The Company adopted ASU 2016-13 during 2013 and implemented the guidance on expected credit losses.

Inventories

Inventories are valued at the lower of cost and reasonable value determined using the first-in, first-out (FIFO) method. Net realized value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of ~~October~~April 3130, ~~2024~~2025, total inventory was $~~168~~215,~~299~~324, consisting of work-in-process of $31100,~~418~~690, finished goods of $~~966~~9,172 and raw materials of $~~135~~105,~~914~~463. As of January 31, ~~2024~~2025, total inventory was $~~168~~212,~~605~~041, consisting of work-in-process of $746,~~466~~255, ~~finished~~ finished goods of $816,~~707~~609 and raw materials of $~~152~~149,~~432~~177.

Property, Plant and Equipment

Property and equipment represent an important component of the Company’s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from 3 to 20 years as follows:

Lab Equipment	~~5-10 years~~	5-10 years
Furniture and fixtures	~~3 years~~	3-5 years
Machinery and equipment	~~10-20 years~~	5-20 years

Intangible Assets

Intangible assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, “Intangibles-Goodwill and Other.” The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company’s acquisitions ~~have~~has also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years. During the year ending January 31, 2025, the Company recorded an impairment charge of $293,038 to its intellectual property.

Goodwill

Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company’s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $1,719,235. On August 31, 2020, in connection with the Company’s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $5,810,640. During the years ~~ended~~ending January 31, ~~2024,~~2025 and ~~2023~~2024, the Company recorded an impairment charge of $~~-0-~~3,302,478 and $~~327~~-0-,~~326,~~ respectively, reducing the Active Intelligence LLC Goodwill to $~~3,302,478~~-0-. As of ~~October~~April 3130, ~~2024,~~2025 and January 31, ~~2024,~~ 2025, Goodwill amounted to $51,~~021~~719,~~713~~535 and $51,~~021~~719,~~713~~535, respectively.

Long-lived Assets

Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between the fair market value of the long-lived asset and the related book value.

Treasury Stock

The Company records the purchase of its treasury shares under the historical cost method. The reissuance of treasury shares are recorded using the average cost method.

Earnings per Share

Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of ~~October~~April 3130, ~~2024~~2025, and ~~2023~~2024, there were 6,~~922~~832,~~833~~308 and 26,~~157~~747,873 common stock equivalents outstanding, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.

Stock-Based Compensation

ASC 718, “Compensation - Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718 was applied to stock-based compensation for both employees and non-employees.

Business Combinations

The Company recognizes the assets acquired, the liabilities assumed, and any non-controlling interest in the acquired entity at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition-related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair value.

Leases

In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a “right-of-use” model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance.

The Company applies ~~the~~ guidance for right-of-use accounting for all leases and records the operating lease liabilities on its balance sheet. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.

Research and Development Expenses

Research and development costs are expensed as incurred.

Income Taxes

Taxes are calculated in accordance with taxation principles currently effective in the United States and Ireland.

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

The Company records net deferred tax assets to the extent they believe these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. In the event the Company was determined that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.12

The Company records net deferred tax assets to the extent they believe these assets will more likely than not be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. In the event the Company was determined that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.

Fair Value Measurements

FASB ASC 820, “Fair Value Measurements and Disclosure” (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of ~~inputs~~input that may be used to measure fair value.

The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and ~~nonfinancial~~non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows:

Level 1	~~Level~~-Observable 1inputs such as quoted market prices in active markets.	~~- Observable inputs such as quoted market prices in active markets.~~
Level 2	~~Level~~-Inputs 2other than quoted prices in active markets that are either directly or indirectly observable.	~~- Inputs other than quoted prices in active markets that are either directly or indirectly observable.~~
Level 3	~~Level~~-Unobservable 3inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions.	~~- Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions.~~

The carrying value of the Company’s financial instruments, including accounts receivable, prepaid expenses, accounts payable and accrued expenses, and deferred revenue approximate their fair value due to the short maturities of these financial instruments.

Recent Accounting Standards

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), The ASU introduces a new credit loss methodology. Current Expected Credit Loss (“CECL”), which requires earlier recognition of credit losses, which also provides additional transparency about credit risk. Since its original issuance in 2016, the FASB has issued several updates to the original ASU. The Company adopted ASU 2016-13 during the year ended January 31, 2024. The adoption of ASU 2016-13 did not have a material impact on the Company’s balance sheet or statement of operations.

The Company has reviewed all other FASB-issued ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods. The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management and certain standards are under consideration.

3.	PROPERTY AND EQUIPMENT

	October 31,			January 31,
	April 30,			January 31,
	2024			2024
	2025			2025
Lab equipment	$	144,585		$	144,585
Machinery and equipment		1,~~384~~389,~~432~~756			1,~~292~~384,~~389~~432
Furniture and fixtures		19,643			19,643
		1,548,660			1,456,617
		1,553,984			1,548,660
Less: Accumulated depreciation		(~~809~~895,~~030~~911	)		(~~681~~853,~~693~~597	)
Net Property and Equipment	$	~~739~~658,~~630~~073		$	~~774~~695,~~924~~063

Depreciation expenses amounted to $~~127~~42,~~337~~314 and $~~133~~40,~~520~~814 for the ~~nine~~three months ending ~~October~~April 3130, ~~2024~~2025, and ~~2023~~2024, respectively. During the ~~nine~~three months ending ~~October~~April 3130, ~~2024~~2025, and ~~2023~~2024, depreciation expenses of $9433,~~644~~851 and $~~101~~30,~~315~~242, respectively, have been allocated to the cost of goods sold.

4.	NOTES PAYABLE

Notes Payable

Active Intelligence, entered into an agreement with the Carolina Small Business Development Fund for a line of credit of $160,000 due October 16, 2028, with interest of 5% per year. The amount assumed was $139,184. The loan requires monthly payments of principal and interest of $1,697. During the ~~nine~~three months ~~ended~~ending ~~October~~April 3130, ~~2024~~2025, the Company made $124,~~007~~461 of principal payments. As of ~~October~~April 3130, ~~2024~~2025, the amount due was $7364,~~242~~962, of which $1617,~~743~~166 is current. As of January 31, ~~2024~~2025, the amount due was $8569,~~249~~132.

On April 3, 2022, the Company entered into a retail installment agreement for the purchase of an automobile. The contract price was $32,274, of which $22,795 was financed. The agreement is for five years bearing interest at 2.95% per annum with payments of $410 per month. The loan is secured by automobile. As of ~~October~~April 3130, ~~2024~~2025, the amount due was $119,~~847~~533, of which $4,~~629~~697 is current. As of January 31, ~~2024~~2025, the amount due was $1510,~~232~~689.

Note payable-related party.

On July 17, 2023, the Company entered an amended Credit Line Note agreement, for an increased $5,000,000 credit line facility to the Company entered on March 17, 2023. Outstanding advances under the Note bears interest at 7% per annum. The promissory note is due and payable in full on March 19, 2026. Interest is payable annually on December 31 of each year during the term of the note. The Company received advances of $300,000 during the nine months ending October 31, 2024. On May 15, 2024, the Company agreed to convert the $300,000 debt. The conversion was made pursuant to the terms of a Conversion Agreement, which provided the conversion of $300,000 of principal and $4,922 of accrued interest. The Company issued 76,230 shares of common stock and 152,460 warrants exercisable at $6.43 per share, resulting in a $368,036 loss on extinguishment. As of ~~October~~April 30, 2025 and January 31, ~~2024~~2025, the balance due was $-0-, respectively. The Company recorded interest expense of $-0- and $4,163 for the ~~nine~~ three months ending ~~October~~April 3130, 2025, and 2024, respectively.

Secured borrowing liability.

On July 19, 2023, the Company entered into an accounts receivable sale agreement for one of its subsidiaries in connection with a bankruptcy claim. The Company received $106,528 and recorded the transaction as a secured loan payable against the account receivable. The sale of the account receivable balance was to an outside third party, whereby if the bankruptcy court does not pay the balance in full, the Company will owe back the unpaid portion. The loan is classified as a current liability as the Company expects the bankruptcy will be resolved in the next twelve months. The loan bears interest at 10%. For the ~~nine~~three months ending ~~October~~April 3130, 2025, and 2024, the Company recorded ~~interest~~an interest expense of $72,~~847~~549 and $2,578, respectively.

Interest expenses for the ~~nine~~three months ~~ended~~ending ~~October~~April 3130, ~~2024~~2025, and ~~2023~~2024, were $175,~~668~~880 and $528,~~601~~618, respectively.

1514

5.	INTANGIBLE ASSETS

As of ~~October~~April 3130, ~~2024~~2025, and January 31, ~~2024~~2025, intangible assets consisted of intellectual property and trademarks, customer base, and license agreement, net of amortization, as follows:

	October 31,			January 31,
	April 30,			January 31,
	2024			2024
	2025			2025
Customer base	$	~~314~~214,~~100~~640		$	~~314~~214,~~100~~640
Intellectual property and trademarks		~~817~~623,~~400~~822			~~817~~623,~~400~~822
Total		1838,~~131,500~~462			1838,~~131,500~~462
Less: Accumulated amortization		(~~549~~592,~~082~~536	)		(~~464~~577,~~220~~370	)
Net Intangible Assets	$	~~582~~245,~~418~~926		$	~~667~~261,~~280~~092

Amortization expenses for the ~~nine~~three months ~~ended~~ending ~~October~~April 3130, ~~2024~~2025, and ~~2023~~2024 amounted to $8415,~~863~~166 and $8428,~~862~~287, respectively. During the year ending January 31, 2025, the Company recorded an impairment charge of $293,038 to its Intellectual property.

	~~Total~~	Total
Year Ended January 31,
2025	$	28,288
2026	$	45,500
2026		113,148
2027		60,666
2027		113,148
2028		60,666
2028		113,148
2029		41,736
2029		94,226
2030		23,596
2030 and thereafter		120,460
2031 and thereafter		13,762
	$	~~582~~245,~~418~~926

6.	RELATED PARTY TRANSACTIONS

Activity during the ~~nine~~three months ~~ended~~ending ~~October~~April 3130, ~~2024~~2025

a) ~~During~~There ~~the~~were ~~nine~~no ~~months~~related ~~ended~~party ~~October~~transactions ~~31,~~during ~~2024, options to purchase 450,000 shares of common stock to executives and employees of~~ the ~~Company at a price of $2.37 and $5.99 per share. The options vest immediately and expire in~~ three ~~years. The fair value of the options issued amounted to $553,335 and was expensed during the nine~~ months ~~ended~~ending ~~October~~April 3130, ~~2024~~2025.

b)Activity Onduring ~~April 19, 2024,~~ the ~~Company~~three months ~~completed~~ending anApril $830,~~400,000~~ equity financing with European investors which included two related parties. The two related parties invested a total of $6,420,000 and received 1,605,000 shares of common stock and warrants to purchase 3,210,000 shares of common stock @ $6.43 per share. See Note 7 for further information.2024

ca) ~~During~~In ~~the~~March ~~nine~~2024, ~~months~~options ~~ended~~to ~~October~~purchase 31390,000 ~~2024,~~shares ~~the~~of ~~Company~~common ~~received~~stock ~~$300,000~~to ~~from~~executives ~~the~~and ~~credit~~employees ~~line~~of ~~facility~~the ~~with~~Company ~~TII~~at ~~Jet~~a ~~Services~~price ~~LDA~~of $2.37 Onand ~~May~~$2.61 ~~15,~~per ~~2024,~~share. ~~the~~The ~~Company~~options ~~converted~~vest ~~the~~immediately ~~debt~~ and ~~accrued~~expire ~~interest~~in ~~into~~three ~~76,230~~years. ~~shares~~The offair ~~common~~value ~~stock~~of ~~and~~the options issued ~~152~~amounted to $422,~~460~~955 ~~warrants~~and towas ~~the~~expensed ~~lender.~~during ~~See~~the ~~Note~~three 4months ~~for~~ending ~~further~~April ~~information~~30, 2024.

db) On ~~June~~April 519, 2024, the Company’s ~~Chief~~completed ~~Financial~~an ~~Officer~~$8,400,000 ~~exercised~~equity ~~87,500~~financing ~~warrants~~with asEuropean investors which included related parties. The related parties invested a ~~cashless~~total ~~conversion~~of $7,120,000 and ~~was~~received ~~issued~~1,780,000 60shares of common stock and warrants to purchase 3,~~085~~560,000 shares of common stock @ $6.43 per share. One related party, a director of the Company, invested $4.5 million which included $500,000 from his son and $700,000 from an entity he controls. The other related party invested $2.62 million from entities controlled by the investor. See Note 7 for further information.

16c) During the three months ending April 30, 2024, the Company received $300,000 from the credit line facility with TII Jet Services LDA. See Note 4 for further information.

~~Activity during the nine months ended October 31, 2023~~15

a) On February 1, 2023, options to purchase 30,000 shares of the Company’s common stock were issued to an executive of the Company at a price of $3.975 per share. The options vest immediately and expire in three years. The fair value of the options issued for services amounted to $75,030 and was expensed during the nine months ended October 31, 2023.

b) On July 17, 2023, the Company entered into an amended Credit Line Note facility with TII Jet Services, LDA, a shareholder of the Company, for a credit facility of $5,000,000 replacing the $2,000,000 facility with the same lender that the Company entered into on March 17, 2023. See Note 4 for further information. TII Jet Services, LDA is owned 100% by a shareholder of the Company.

c) In September and October 2023, options to purchase 374,500 shares of common stock to executives and directors of the Company at a price of $1.93, $2.12 and $2.65 per share. The options vest immediately and expire in three years. The fair value of the options issued amounted to $424,826 and was expensed during the nine months ended October 31, 2023.

d) On October 31, 2023, warrants to purchase 87,500 shares of the Company’s common stock were issued to the Company’s Chief Financial Officer at a price of $1.93 per share. The warrant expires in three years. The fair value of the warrants issued amounted to $93,450 and was expensed during the nine months ended October 31, 2023.

7.	STOCKHOLDERS’ EQUITY

Preferred Stock

On January 15, 2016, the board of directors of the Company approved a certificate of amendment to the articles of incorporation and changed the authorized capital stock of the Company to include and authorize 10,000,000 shares of Preferred Stock, par value $0.001 per share.

On May 24, 2019, the board of directors created a series of preferred stock consisting of 2,500,000 shares designated as the Series A Convertible Preferred Stock (“Series A Preferred Stock”). On June 20, 2019, the Series A preferred Stock was terminated, and the 2,500,000 shares were restored to the status of authorized but unissued shares of Preferred Stock, without designation as to series, until such stock is once more designated as part of a particular series by the board of directors.

Common Stock

On June 25, 2019, the Company effected a one-for-four reverse stock split, pursuant to which each outstanding share of common stock was changed into 0.25 shares of common stock, and the Company decreased its authorized common stock in the same ratio from 100,000,000 to 25,000,000 shares.

On January 27, 2020, the Company amended its Articles of Incorporation to increase its authorized common shares from 25,000,000 authorized shares to 250,000,000 authorized shares.

On July 26, 2022, the Board of Directors of the Company approved a 7-for-6 forward stock split, effective for trading purposes as of August 12, 2022, pursuant to which each shareholder as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. Pursuant to the operation of the amendment providing for the forward stock split filed with the Secretary of State of Nevada on August 4, 2022, the authorized common stock of the Company was increased from 250,000,000 shares to 291,666,666 shares in connection with the forward split.

Activity during the ~~Nine~~Three Months ~~Ended~~ ~~October~~Ending 31April 30, ~~2024~~2025

(a) As of ~~October~~April 3130, ~~2024~~2025, the Company holds ~~zero~~23,900 shares of treasury stock. On ~~September~~March 104, ~~2024~~2025, 103,~~000~~500 shares of treasury stock held by the Company were issued to anemployees ~~investor relations firm~~ for services rendered. The Company recorded an expense of $3824,~~700~~360 during the ~~nine~~three months ~~ended~~ending ~~October~~April 3130, ~~2024~~2025, in connection with the transaction.

	(b)	On February 8, 2025, the Company entered into an agreement with a consultant to provide consulting services to the Company’s Board of Directors. The Company issued 5,000 shares of the Company’s common stock to the consultant, valued at $39,050 and expensed during the three months ending April 30, 2025. The shares were issued from the treasury shares held by the Company. The term of the agreement is for twelve months.

(c)

In February 2025, the Company’s outside counsel exercised 58,433 warrants as a cashless conversion and the Company issued 46,961 shares of common stock.

Activity during the Three Months Ending April 30, 2024

	(a)	As of April 30, 2024, the Company held 10,000 of its shares comprising $32,641 of treasury stock. There was no activity during the three months ending April 30, 2024.

(b)

On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors (the “Offering”) of 2,100,000 units (“Units”), at a price of $4.00 per Unit, consisting of one share of common stock (“Shares”) and a Warrant to purchase two Shares of common stock, the Warrant having an exercise price of $6.43, are exercisable by payment of the exercise price in cash only and expire April 19, 2029, five years from the date of issuance (“Warrants”). The offering was made solely to investors residing outside the United States and was not registered under the Security Act of 1933, as amended, (the “Security Act”), or the security law of any jurisdiction, including outside the United States, but was made privately by the Company pursuant to the exemptions from registration provided in the SEC’s Regulation S and other exemptions under the Securities Act.

(c) On May 15, 2024, the Company agreed to convert $300,000 of debt and $4,922 of accrued interest under the Credit Line Note agreement. The conversion was made pursuant to the terms of a Conversion Agreement, which provided the conversion of the debt and accrued interest. Company issued 76,230 shares of common stock and 152,460 warrants exercisable at $6.43 per share resulting in a loss on settlement of $368,036.

(d) On June 5, 2024, the Company’s Chief Financial Officer exercised 87,500 warrants as a cashless conversion and was issued 60,085 shares of common stock.

Activity during the Nine Months Ended October 31, 2023

(a) As of October 31, 2023, the Company held 10,000 of its shares comprising $32,641 of treasury stock. There was no activity during the nine months ended October 31, 2023.

8.	OPTIONS and WARRANTS

Warrants

On March 7, 2023, the Company issued 30,000 warrants to purchase the Company’s common shares to Barandnic Holdings Ltd. for services provided. The warrants are exercisable at a price of $4.00 per share and expire five years from the date of issuance. On October 27, 2023, the Company issued 145,833 warrants to purchase the Company’s common shares to management (87,500 warrants were issued to the Chief Financial Officer) and non-employees of the Company. The warrants are exercisable at a price of $1.93 per share and expire in three years from the date of issuance. These warrants replace previously issued warrants that have now been cancelled. The Company used the Black-Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rates of 152.10-174.45%; and a risk-free rate of 4.31%-4.84%. Non-cash compensation for the year ended January 31, 2024, amounted to $242,840.

On April 19, 2024, in connection with a private placement of the Company’s common stock, the Company issued 4,200,000 warrants. The warrants are exercisable at a price of $6.43 per share and expire five years from the date of issuance.

On May 15, 2024, the Company issued 152,460 warrants in connection with extinguishment of debt of $300,000 and accrued interest. The warrants are exercisable at a price of $6.43 per share and expire five years from the date of issuance. Non-cash expense of $390,145 is included in loss on extinguishment of debt.

On June 5, 2024, the Company’s Chief Financial Officer exercised 87,500 warrants as a cashless conversion and the Company issued 60,085 shares of common stock.

On September 10, 2024, the Company issued 50,000 warrants to an investor relations firm. The warrants are exercisable at a price of $4.00 per share and expire three years from the date of issuance. The Company recorded a non-cash expense of $94,650 during the nine months ended October 31, 2024. The agreement is for twelve months and includes the issuance of 10,000 treasury shares and monthly payments of $12,500. The warrants and shares vest immediately and because they are non-forfeitable, the expense was recognized immediately.16

~~The~~On ~~Company~~September ~~used~~10, 2024, the ~~Black~~Company ~~Scholes valuation~~issued ~~model~~50,000 warrants to ~~record~~an ~~fair~~investor ~~value~~relations firm. The warrants are exercisable at a price of $4.00 per share and expire three years from the ~~value~~date of ~~the~~issuance. ~~warrants~~The ~~issued~~Company recorded a non-cash expense of $94,650 during the ~~nine~~year ~~months~~ending ~~ended~~January ~~October~~ 31, ~~2024~~2025. The ~~valuation~~agreement ~~model~~is ~~used~~for atwelve ~~dividend~~months ~~rate~~and includes the issuance of ~~0%;~~10,000 ~~expected~~treasury ~~terms~~shares and monthly payments of 1$12,500.~~5-2.5~~ ~~years;~~The ~~volatility~~warrants ~~rates~~and ofshares ~~105.98%-145.05%;~~vest immediately and ~~risk~~because they are non-~~free~~forfeitable, ~~rates~~the expense was recognized immediately. The Company cancelled the warrants as of 3January 31, 2025.~~65%-4.45%.~~

~~The~~Non-cash ~~following~~compensation ~~table~~for ~~summarizes~~ the ~~changes~~year ending inJanuary ~~the~~31, ~~warrants~~2025, ~~outstanding~~amounted ~~and the related price of the shares of the Company’s common stock issued~~ to ~~non-employees of the Company during the nine months ended October 31~~$484, ~~2024~~975.

				Exercise		Remaining		Intrinsic
	Shares			Price		Life		Value
Outstanding, January 31, 2023		1,307,671		$	6.43		3.34 years	$	-
Granted		175,833			2.28		2.97 years		-
Expired/Cancelled		(200,466	)		6.33		-		-
Exercised		-			-		-		-
Outstanding, January 31, 2024		1,283,038			5.88		2.97 years		-
Granted		4,402,460			6.40		4.72 years		-
Expired/Cancelled		-			-		-		-
Exercised		(87,500	)		1.93		-		-
Outstanding- October 31, 2024		5,597,998		$	6.35		3.93 years	$	314,199
Exercisable - October 31, 2024		5,597,998		$	6.35		3.93 years	$	314,199

The Company used the Black Scholes valuation model to record fair value of the value of the warrants issued during the year ending January 31, 2025. The valuation model used a dividend rate of 0%; expected terms of 1.5-2.5 years; volatility rates of 105.98%-145.05%; and risk-free rates of 3.65%-4.45%.

19The following table summarizes the changes in the warrants outstanding and the related price of the shares of the common stock issued to non-employees of the Company during the three months ending April 30, 2025 and the year ending January 31, 2025.

The following table summarizes additional information relating to the warrants outstanding as of October 31, 2024:

				Exercise		Remaining		Intrinsic
	Shares			Price		Life		Value
Outstanding, January 31, 2024		1,283,038		$	5.88		2.97 years	$	-

Granted		4,402,460			6.40		4.72 years		-

Expired/Cancelled		(50,000	)		4.00		-		-

Exercised		(88,525	)		1.98		-		-

Outstanding, January 31, 2025		5,546,973			6.37		3.68 years		-

Granted		-			-		-		-

Expired/Cancelled		-			-		-		-

Exercised		(58,333	)		1.93		-		-

Outstanding- April 30, 2025		5,488,640		$	6.42		3.98 years	$	2,531,538

Exercisable - April 30, 2025		5,488,640		$	6.42		3.98 years	$	2,531,538

				Weighted Average		Weighted Average				Weighted Average
Range of Exercise		Number		Remaining Contractual		Exercise Price for Shares		Number		Exercise Price for Shares		Intrinsic
Prices		Outstanding		Life (Years)		Outstanding		Exercisable		Exercisable		Value
$	4.00		80,000		3.04	$	4.00		80,000	$	4.00	$	65,700
$	6.43		5,434,665		3.96	$	6.43		5,434,665	$	6.43	$	-
$	1.93		58,333		1.99	$	1.93		58,333	$	1.93	$	248,499
$	7.50		25,000		3.02	$	7.50		25,000	$	7.50	$	-
			5,597,998			$	6.35		5,597,998	$	6.35	$	314,199

The following table summarizes additional information relating to the warrants outstanding as of April 30, 2025:

				Weighted Average		Weighted Average				Weighted Average
Range of Exercise		Number		Remaining Contractual		Exercise Price for Shares		Number		Exercise Price for Shares		Intrinsic
Prices		Outstanding		Life(Years)		Outstanding		Exercisable		Exercisable		Value
$	4.00		30,000		2.85	$	4.00		30,000	$	4.00	$	86,400
$	6.43		5,433,640		3.47	$	6.43		5,433,640	$	6.43	$	2,445,138
$	7.50		25,000		2.77	$	7.50		25,000	$	7.50	$	-
			5,488,640			$	6.42		5,488,640	$	6.42	$	2,531,538

Options

On November 1, 2021, the Board of Directors adopted the 2021 Employee Stock Option Plan (the “Plan”). The Company has reserved 408,333 shares for issuance and sale upon the exercise of stock options. In accordance with the Plan, on February 1, 2022, the Company reserved an additional 233,333 shares and on February 1, 2023, the Company reserved an additional 233,333 shares. The options vest immediately and expire in three years. Under the Plan, options may be granted which are intended to qualify as Incentive Stock Options (“ISO’s”) under Section 422 of the Internal Revenue Code of 1986 (the “Code”) or which are not (“non-ISO’s”) intended to qualify as Incentive Stock Options thereunder. The Plan also provides for restricted stock awards representing shares of common stock that are issued subject to such restrictions on transfer and other incidents of ownership and such forfeiture conditions as the Board of Directors, or the committee administering the Plan composed of directors who qualify as “independent” under Nasdaq rules, may determine. On November 3, 2021, the Company filed a Registration Statement on Form S-8, to register under the Securities Act of 1933, as amended the 408,333 shares of common stock reserved for issuance under the Plan.

On March 20, 2024, our Board of Directors adopted an amendment to the Company’s Employee Stock Option Plan (the “Plan”) increasing the number of shares of common stock subject to the Plan (as of March 20, 2024, 875,000 shares) to 1,400,000 shares (the “Amendment”). The Company will submit the Amendment to the Plan to our stockholders for adoption and approval at the 2025 Annual Meeting. If the Amendment is not approved by stockholders within one year of adoption, the increase in shares subject to the Plan will be void, together with any options issued following March 20, 2024, in the period pending approval of the Plan by our stockholders. As of October 31, 2024, 75,166 shares remain available for issuance of options under the Plan.17

~~During~~On ~~the~~March ~~nine months ended October 31~~20, 2024, ~~450,000~~our ~~options~~Board toof ~~purchase~~Directors adopted ~~shares~~an ofamendment to the Company’s ~~common~~Employee ~~stock~~Stock ~~were~~Option ~~issued~~Plan to(the ~~executive~~“Plan”) ~~officers~~increasing ~~and~~the ~~employees~~number atof ~~prices~~ shares of ~~$2.37-~~common stock ~~$5.99~~subject ~~per~~to ~~share.~~the ~~The~~Plan ~~options~~(as ~~vest~~of ~~immediately~~March ~~and~~20, ~~expire~~2024, ~~three~~875,000 ~~years~~shares) ~~from~~to ~~the~~1,400,000 ~~date~~shares of(the ~~issuance~~“Amendment”). The ~~fair~~Company ~~value~~submitted the ofAmendment to the ~~options issued~~Plan ~~for~~to ~~services~~our ~~amounted~~stockholders tofor ~~$553,335~~adoption and ~~was~~approval ~~recorded~~at ~~during~~ the ~~nine~~2025 ~~months~~Annual ~~ended October 31, 2024~~Meeting. The ~~Company~~Amendment ~~used~~was ~~the~~approved ~~Black-Scholes~~by the ~~valuation~~stockholders ~~model~~on toJanuary ~~record~~23, ~~the fair value~~2025. ~~The~~As ~~valuation~~of ~~model~~April ~~used~~30, a2025, ~~dividend~~with ~~rate~~the ofFebruary ~~0%;~~1, ~~expected~~2025 ~~term~~automatic issuance of ~~1.5~~shares ~~years;~~available ~~volatility~~under ~~rate~~the Plan, of276,332 ~~97.83%-114.86%;~~shares ~~and~~remain aavailable ~~risk-free~~for ~~rate~~issuance of 3options under the Plan.~~65%-4.87%.~~

During the year ~~ended~~ending January 31, ~~2024~~2025, ~~404~~689,~~500~~584 options to purchase shares of the Company’s common stock were issued to executive officers and employees at prices of $12.9337- $38.~~975~~ 07 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued for ~~services~~ services amounted to $~~499~~1,~~856~~408,935 and ~~was~~were recorded during the year ~~ended~~ending January 31, ~~2024~~2025. The Company used the Black-Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility ~~rates~~rate of ~~121~~97.5283%-~~143~~114.5486%; and a risk-free rate of 34.00%-4.587%.

20The following table summarizes the changes in outstanding options and the related price of the shares of the Company’s common stock issued to employees of the Company. See Note 7 for the issuance of related party options.

The following table summarizes the changes in options outstanding and the related price of the shares of the Company’s common stock issued to employees of the Company. See Note 7 for the issuance of related party options.

				Exercise		Remaining		Intrinsic
	Shares			Price		Life		Value
Outstanding, January 31, 2024		874,835		$	3.23		2.31 years

Granted		689,584			4.40		1.93 years		-

Expired/Cancelled		(190,751	)		-		-

Exercised		-			-		-

Outstanding, January 31, 2025		1,373,668			3.68		1.90 years

Granted		-			-		-

Expired/Cancelled		-			-		-

Exercised		-			-		-

Outstanding- April 30, 2025		1,373,668		$	3.68		1.65 years	$	4,550,248

Exercisable - April 30, 2025		1,373,668		$	3.68		1.65 years	$	4,550,248

			Exercise		Remaining		Intrinsic
	Shares		Price		Life		Value
Outstanding, January 31, 2023		470,335	$	4.13		2.53 years
Granted		404,500		2.18		2.68 years		-
Expired/Cancelled		-		-		-
Exercised		-		-		-
Outstanding, January 31, 2024		874,835		3.23		2.31 years
Granted		450,000		2.74		1.93 years
Expired/Cancelled		-		-		-
Exercised		-		-		-
Outstanding- October 31, 2024		1,324,835	$	3.07		1.68 years	$	4,139,797
Exercisable - October 31, 2024		1,324,835	$	3.07		1.68 years	$	4,139,797

The following table summarizes additional information relating to the options outstanding as of April 30, 2025:

The following table summarizes additional information relating to the options outstanding as of October 31, 2024:

						Weighted Average				Weighted Average
Range of Exercise		Number		Weighted Average		Exercise Price for Shares		Number		Exercise Price for Shares		Intrinsic
Prices		Outstanding		Life(Years)		Outstanding		Exercisable		Exercisable		Value

$	1.93		214,500		1.49	$	1.93		214,500	$	1.93	$	1,061,775
$	2.12		140,000		1.49	$	2.12		140,000	$	2.12	$	666,400
$	2.37		195,000		1.88	$	2.37		195,000	$	2.37	$	879,450
$	2.61		195,000		1.88	$	2.61		195,000	$	2.61	$	828,750
$	2.65		20,000		1.39	$	2.65		20,000	$	2.65	$	84,600
$	2.75		30,000		1.76	$	2.75		30,000	$	2.75	$	123,900
$	3.59		35,000		2.42	$	3.59		35,000	$	3.59	$	115,150
$	3.75		57,500		0.61	$	3.75		57,500	$	3.75	$	179,975
$	3.98		30,000		0.76	$	3.98		30,000	$	3.98	$	87,000
$	4.09		78,750		0.25	$	4.09		78,750	$	4.09	$	219,713
$	4.12		50,000		0.61	$	4.12		50,000	$	4.12	$	138,000
$	4.50		58,334		0.25	$	4.50		58,334	$	4.50	$	138,835
$	5.99		30,000		2.17	$	5.99		30,000	$	5.99	$	26,700
$	7.34		180,918		2.73	$	7.34		180,918	$	7.34	$	-
$	8.07		58,666		2.73	$	8.07		58,666	$	8.07	$	-

			1,373,668		1.65	$	3.68		1,373,668	$	3.68	$	4,550,248

						Weighted Average				Weighted Average
Range of Exercise		Number		Weighted Average		Exercise Price for Shares		Number		Exercise Price for Shares		Intrinsic
Prices		Outstanding		Life(Years)		Outstanding		Exercisable		Exercisable		Value
$	1.93		214,500		1.99	$	1.93		214,500	$	1.93	$	913,770
$	2.12		140,000		1.99	$	2.12		140,000	$	2.12	$	569,800
$	2.37		195,000		2.38	$	2.37		195,000	$	2.37	$	744,900
$	2.61		195,000		2.38	$	2.61		195,000	$	2.61	$	698,100
$	2.65		20,000		1.88	$	2.65		20,000	$	2.65	$	70,800
$	2.75		30,000		2.25	$	2.75		30,000	$	2.75	$	103,200
$	3.59		35,000		2.92	$	3.59		35,000	$	3.59	$	91,000
$	3.75		57,500		1.10	$	3.75		57,500	$	3.75	$	140,300
$	3.98		30,000		1.25	$	3.98		30,000	$	3.98	$	66,300
$	4.09		78,750		0.75	$	4.09		78,750	$	4.09	$	165,375
$	4.12		50,000		1.10	$	4.12		50,000	$	4.12	$	103,500
$	4.16		144,085		0.22	$	4.16		144,085	$	4.16	$	292,901
$	4.50		58,334		0.75	$	4.50		58,334	$	4.50	$	98,584
$	4.58		46,668		0.22	$	4.58		46,668	$	4.58	$	75,267
$	5.99		30,000		2.67	$	5.99		30,000	$	5.99	$	6,000
			1,324,837		1.68	$	3.07		1,324,837	$	3.07	$	4,139,797

9.	SEGMENT REPORTING

We organize and manage our business by the following two segments which meet the definition of reportable segments under ASC280-10, Segment Reporting: Sales of Goods and Services. These segments are based on the customer type of products or services provided and are the same as our business units. Separate financial information is available and regularly reviewed by our chief operating officer- decision maker, who is our chief executive officer, in making resource allocation decisions for our segments. Our chief operating officer- decision maker evaluates segment performance to the GAAP measure of gross profit.

	Nine Months Ended				Three Months Ended
		Three Months
	October 31,				October 31,
		Ended
	2024		2023		2024		2023
		April 30,
Net sales
		2025		2024
Pocono Pharmaceuticals	$	1,497,158	$	1,395,667	$	645,796	$	427,841
Net sales
4P Therapeutics		-		165,034		-		-
Pocono Pharmaceuticals	$	667,432	$	408,532
		1,497,158		1,560,701		645,796		427,841
4P Therapeutics		-		-
Gross profit
		667,432		408,532
Pocono Pharmaceuticals		457,373		561,083		191,029		161,022
Gross profit
4P Therapeutics		-		119,794		-		(1,301	)
Pocono Pharmaceuticals		251,981		164,786
		457,373		680,877		191,029		159,721
4P Therapeutics		-		-
Operating expenses
		251,981		164,786
Selling, general and administrative-Pocono Pharmaceuticals		494,723		424,139		173,655		151,856
Operating expenses
Selling, general and administrative-4P Therapeutics		78,499		92,075		23,896		29,238
Selling, general and administrative-Pocono Pharmaceuticals		151,528		154,394
Selling, general and administrative-Corporate		1,980,933		2,356,646		539,551		1,175,296
Selling, general and administrative-4P Therapeutics		19,999		24,354
Research and development-4P Therapeutics		2,629,278		1,397,055		880,768		551,053
Selling, general and administrative-Corporate		810,525		900,980
		5,183,433		4,269,915		1,617,870		1,907,443
Research and development-4P Therapeutics		683,426		974,535
Depreciation and Amortization
		1,665,478		2,054,263
Pocono Pharmaceuticals	$	175,365	$	165,632	$	60,871	$	53,807
Depreciation and Amortization
Corporate		9,032		10,495		3,011		3,501
Pocono Pharmaceuticals	$	48,213	$	56,823
4P Therapeutics		27,802		42,255		9,267		9,963
Corporate		-		3,011
	$	212,199	$	218,382	$	73,149	$	67,271
4P Therapeutics		9,267		9,267
	$	57,480	$	69,101

The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.

	Nine Months Ended				Three Months Ended
	Three Months
	October 31,				October 31,
	Ended
	2024		2023		2024		2023
	April 30,
Net sales
	2025		2024
United States	$	1,497,158	$	1,560,701	$	645,796	$	427,841
Net sales
Outside the United States		-		-		-		-
United States	$	667,432	$	408,532
	$	1,497,158	$	1,560,701	$	645,796	$	427,841
Outside the United States		-		-
	$	667,432	$	408,532

	October 31,		January 31,
	2024		2024
Property and equipment, net of accumulated depreciation
United States	$	739,639	$	774,924
Outside the United States		-		-
	$	739,639	$	774,924
Assets
Corporate	$	5,678,388	$	339,552
Pocono Pharmaceuticals		4,990,605		5,079,293
4P Therapeutics		1,874,209		2,098,309
	$	12,543,202	$	7,517,154

		April 30,		January 31,
		2025		2025
Property and equipment, net of accumulated depreciation
United States	$	658,073	$	695,063
Outside the United States		-		-
	$	658,073	$	695,063
Assets
Corporate	$	2,869,688	$	4,205,577
Pocono Pharmaceuticals		1,427,893		1,404,285
4P Therapeutics		1,854,600		1,859,793
	$	6,152,181	$	7,469,655

10.	COMMITMENTS AND CONTIGENCIES

Employment Agreements

The Company entered into three-year employment agreements with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022. The agreement also provides that the executives will continue as directors and officers of the Company for the respective terms thereof. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days’ notice given prior to the expiration of the initial term or any one-year extension. For their services to the Company during the term of the agreement, Mr. Sheridan and Mr. Melnik will receive an annual salary of $250,000 per annum, commencing on the effective date of the agreement. Mr. Sheridan and Mr. Melnik will also receive a performance bonus of 3.5% of net income before income taxes. As of July 31, 2022, the Company and Mr. Sheridan and Mr. Melnik mutually agreed to reduce their annual salary to $150,000. These agreements, and the employment of Mr. Goodman, automatically renew for one-year terms following expiration of the initial three-year terms and each successive one-year term.

The Company entered into a three-year employment agreement with Gerald Goodman, our CFO, effective February 1, 2022. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days’ notice given prior to the expiration of the initial term or any one-year extension. For his services to the Company during the term of the agreement, Mr. Goodman will receive an annual salary of $210,000 per annum, commencing on the effective date of the agreement. As of July 31, 2022, the Company and Mr. Goodman mutually agreed to reduce his annual salary to $110,000.

2320

Kindeva Drug Delivery Agreement

On January 154, 2024, ~~the~~ Nutriband signed a commercial development and clinical supply agreement for their lead product, Aversa Fentanyl, with Kindeva Drug Delivery, L.P. (“Kindeva”). Under this agreement, Kindeva will perform commercial manufacturing process development, ~~and~~ manufacturing of clinical supplies for the human abuse liability clinical study, and development of chemistry, manufacturing and controls (CMC) information required by the FDA in support of a New Drug Application (“NDA”). ~~The~~As ~~new~~of ~~agreement~~January ~~replaces~~31, ~~the~~2025, ~~previous~~Nutriband ~~feasibility~~has ~~agreement between~~incurred ~~the~~expenses ~~two~~of ~~companies~~$3.0 million under this agreement. The ~~estimated~~Company ~~cost~~expects approximately $5.2 million to complete the ~~commercial~~ development. ~~and~~On ~~clinical~~February ~~manufacturing~~4, 2025, the agreement iswas ~~approximately~~amended to reduce the ~~$8.1~~hourly ~~million~~rate ~~and~~for the ~~expected~~labor ~~timing~~on ofthe ~~FDA~~project ~~submission~~in isexchange ~~twelve~~for toa ~~eighteen~~milestone ~~months.~~payment Aspayable ofupon ~~October~~FDA ~~31,~~approval. ~~2024,~~Under ~~Nutriband~~the ~~has~~amended ~~incurred~~agreement, ~~expenses~~the remaining budget as of $1April 30,~~789~~ 2025,~~232.~~ ~~Approximately~~through NDA submission for the current workplan was reduced to $6.3.2 million. ofThe ~~costs~~amended isagreement also ~~expected~~includes ina ~~the~~milestone ~~future~~payment toof ~~finalize~~$3.0 ~~the~~million ~~submission~~to be paid to Kindeva when the Company receives FDA approval.

Lease Agreement

On February 1, 2022, Pocono Pharmaceuticals entered into a lease agreement with Geometric Group, LLC for 12,000 square feet of warehouse space currently occupied by Active Intelligence. The monthly rental is $3,000 and the lease expires on January 31, 2025. The lease ~~can~~has bebeen extended for an additional three years at the same monthly rental.

Sorrento Therapeutics, Inc. Agreement

On July 25, 2023, 4P Therapeutics assigned its claim under the bankruptcy proceedings from Sorrento Therapeutics Inc. and received proceeds of $106,528. The amount due under the claim was $118,675 and 4P Therapeutics recorded a reserve for bad debts of $118,675 during the year ended January 31, 2024. Under the agreement with the buyer of the claim, 4P Therapeutics will make proportional restitution and/or repayment of the purchase amount to the extent the claim is disallowed, reduced or not paid at the same time or distribution rate as other general unsecured claims against the Debtor are paid. The Company has recorded the amount of the proceeds as a secured loan payable to the factor as of ~~October~~April 3130, ~~2024~~2025.

Legal Proceedings

The Company is currently a defendant in a lawsuit initiated by Joseph Gunnar, LLC (“Gunnar”) and Lucosky Brookman LLP (“LB”) in the Supreme Court of the State of New York, New York County, under Index No.654633/2023. The lawsuit alleges multiple allegations such as breach of contract, fraudulent activities, and tortious interference and seeks damages following the Company’s termination of an engagement letter for assistance with a public stock offering. Gunnar is seeking over $500,000 in damages plus punitive damages, while LB is demanding reimbursement of legal fees.

In response, the Company denies all allegations, alleging that the engagement letter was unenforceable, and its termination was legally justified. The Company has also initiated counterclaims against Joseph Gunnar & Co., accusing them of intentional interference and breach of fiduciary duty, and is seeking $1,000,000 for each claim along with a declaratory judgment affirming the legality and justification of the termination. The plaintiffs have denied these counterclaims.

Currently, there are no pending hearings or motions, asand ~~both~~the ~~parties~~case ~~are~~is ~~engaged~~ in the discovery ~~and~~stage. ~~are~~In ~~attempting~~early to2024, ~~resolve~~ the ~~matter amicably. The~~ plaintiffs proposed a settlement offer of $100,000. ~~that~~The ~~was~~Company has ~~rejected~~not byresponded ~~the~~to ~~Company~~that proposed settlement offer.

11.	SUBSEQUENT EVENTS

~~(a)~~The ~~Subsequent~~Company tohas evaluated ~~October~~subsequent ~~31,~~events ~~2024,~~through the ~~Company~~filing ~~purchased~~of ~~20,400~~this ~~shares~~Quarterly ofReport ~~its~~on ~~common~~Form ~~stock~~10-Q ~~for~~and ~~$99,045~~determined ~~and~~there ~~recorded~~have ~~the~~been ~~transaction~~no asevents ~~Treasury~~that ~~Stock~~have occurred that would require adjustments to our disclosures in the consolidated financial statements.

2421

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD LOOKING STATEMENTS

This report contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements but are not deemed to represent an all-inclusive means of identifying forward-looking statements as denoted in this report. Additionally, statements concerning future matters are forward-looking statements.

Although forward-looking statements in this report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the headings “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our annual report on Form 10-K for the year ended January 31, ~~2024~~2025, in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Form 10-Q and information contained in other reports that we file with the SEC. You are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this report.

We undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date of this report, except as required by law. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this quarterly report, which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

Overview

~~AVERSA™~~Nutriband Inc. (the “Company”, “Nutriband”, “we” or “us”), was incorporated in Nevada in January 2016. Our primary business is the development of a portfolio of transdermal pharmaceutical products. Our development pipeline primarily consists of transdermal products that are based on our proprietary AVERSA™ abuse deterrent transdermal technology that we believe can be incorporated into existing transdermal patches that contain drugs that are susceptible to abuse and misuse such as opioid and stimulant drugs.

~~Our~~The ~~primary~~Company’s ~~business~~revenues isare ~~the~~based ~~development~~on ~~of a portfolio~~providing ofservices ~~transdermal~~through ~~pharmaceutical products. Our lead product is~~ our ~~abuse~~subsidiaries ~~deterrent~~Pocono ~~fentanyl~~Pharmaceuticals ~~transdermal~~operating ~~system~~as ~~which~~Active ~~will~~Intelligence ~~require approval from the Food~~ and ~~Drug~~4P ~~Administration (“FDA”) and substantial additional capital for research and development~~Therapeutics. ~~Our~~Pocono ~~abuse deterrent~~Pharmaceuticals ~~transdermal~~provides ~~product~~contract ~~under~~manufacturing ~~development~~services ~~has~~for ~~the~~health, ~~potential~~wellness ~~to provide clinicians~~ and ~~patients with an extended~~over-~~release transdermal fentanyl product for use in managing chronic pain requiring around~~ the-counter ~~clock~~pharmaceutical ~~opioid~~customers ~~therapy combined with properties designed to deter the abuse~~ and ~~misuse~~4P ofTherapeutics ~~fentanyl patches. In addition, we believe that our abuse deterrent technology can be broadly applied to various transdermal~~performs ~~products~~contract research and ~~our strategy is to follow the~~ development ofrelated ~~our~~services ~~abuse deterrent fentanyl transdermal system with the development of abuse deterrent transdermal products~~ for ~~pharmaceuticals~~pharmaceutical ~~that~~and ~~have~~medical ~~risks~~devices ~~or a history of abuse~~customers. We ~~received~~manage onand ~~January~~evaluate ~~28,~~our ~~2022~~operations, ~~an Issue Notification~~ ~~from the United States Patent~~ and ~~Trademark~~report ~~Office (USPTO) for~~ our ~~United~~financial ~~States patent entitled~~results, ~~“Abuse~~through ~~and~~these ~~Misuse~~two ~~Deterrent~~separate ~~Transdermal System,” that protects our Aversa™ technology platform~~subsidiaries.

25Our principal offices are located in Orlando, Florida, and our subsidiary, Pocono Pharmaceuticals, has a manufacturing facility in Cherryville, North Carolina. We primarily operate and derive most of our revenues in the United States.

~~Through~~Recent October 31, 2018, our business was the development of a line of consumer and health products that are delivered through a transdermal or topical patch. Following our acquisition of 4P Therapeutics on August 1, 2018, our focus expanded to include prescription pharmaceuticals, and we are seeking to develop and seek FDA approval on a number of transdermal pharmaceutical products under development by 4P Therapeutics.Developments

~~Most~~On ofFebruary ~~our~~13, ~~planned~~2025, ~~consumer~~we ~~products~~signed ~~require~~an addendum to ~~FDA~~the ~~approval~~Commercial Development and Clinical Supply Agreement for ~~sale~~our inlead ~~the~~product, ~~United~~Aversa™ ~~States~~Fentanyl, ~~and~~being wedeveloped ~~have~~with ~~not~~our ~~sought~~partner, Kindeva toDrug ~~obtain~~Delivery, a leading global contract development and wemanufacturing doorganization ~~not~~(CDMO) ~~plan~~focused toon ~~seek~~drug-device tocombination products. Nutriband ~~obtain,~~and ~~FDA~~Kindeva ~~approval~~have revised their agreement to ~~market~~formalize their exclusive product development partnership and long-term ~~these~~commitment ~~products~~based inon ~~the~~shared ~~United~~development ~~States~~costs atin ~~this~~exchange ~~time~~for milestone payments. ~~Following~~The ~~our~~development ~~acquisition~~work ofbeing ~~selected~~conducted ~~assets~~under ~~from~~this ~~Pocono~~agreement supports ~~Coated~~the ~~Products,~~development ~~LLC~~of ~~(“Pocono”), we~~Nutriband’s ~~are~~AVERSA™ ~~primarily~~abuse-deterrent ~~focused~~technology onin ~~providing~~general, ~~contract~~which ~~manufacturing~~can ~~services~~be ~~and~~utilized ~~consulting~~to ~~services~~incorporate aversive agents into transdermal patches to ~~3rd~~prevent ~~party~~the ~~brands~~abuse, ~~with~~diversion, nomisuse, ~~intention at~~and ~~this~~accidental ~~time~~exposure toof ~~launch~~drugs ~~our~~with ~~own~~abuse ~~consumer~~potential including ~~products~~opioids and stimulants.

4P Therapeutics has not generated any revenue from any of its products under development. Rather, prior to our acquisition, 4P Therapeutics generated revenue to provide cash for its operations through contract research and development and related services for a small number of clients in the life sciences field on an as-needed basis. We are, for the near term, continuing this activity, although we do not anticipate that it will generate significant revenues and, since our acquisition, it has generated minor gross margins. We have no long-term contractual obligations, and either party can terminate at any time.22

~~With~~On April 19, 2024, the ~~change~~Company incompleted ~~our~~an ~~focus~~$8,400,000 equity ~~our~~financing ~~capital~~with ~~requirements have~~European ~~increased~~investors ~~substantially~~(the “Offering”) of 2,100,000 units (“Units”), at a price of $4.00 ~~The~~per Unit, ~~process~~each Unit consisting of ~~developing~~one ~~pharmaceutical~~share ~~products~~of common stock (“Shares”) and ~~submitting~~a ~~them~~Warrant ~~for~~to ~~FDA~~purchase ~~approval~~two isShares ~~both~~of ~~time~~common ~~consuming~~stock, the ~~and~~Warrants ~~expensive,~~having ~~with~~an noinitial ~~assurance~~exercise price of ~~obtaining~~$6.43, ~~approval~~are ~~from~~exercisable ~~the~~by ~~FDA~~payment toof ~~market~~the ~~our~~exercise ~~product~~price in cash only and expire April 19, 2029, five years from the ~~United~~date ~~States~~of issuance (“Warrants”). WeThe ~~will~~Offering ~~require~~was ~~approximately $13~~made ~~million~~solely ~~for~~to ~~research~~investors resident outside the United States and ~~development~~was not registered under the Securities Act of ~~our~~1933, ~~abuse~~as ~~deterrent~~amended ~~fentanyl~~(the ~~transdermal~~“Securities ~~system~~Act”), or the securities laws of any jurisdiction, including ~~clinical~~any ~~manufacturing~~jurisdiction ~~and~~outside ~~clinical trials~~the ~~that~~United ~~need~~States, tobut bewas ~~completed~~made privately by the Company pursuant to ~~obtain~~the ~~FDA~~exemptions from ~~approval.~~registration ~~However,~~provided in the ~~total~~SEC’s ~~cost~~Regulation ~~could~~S beand ~~substantially~~other inexemptions ~~excess~~under ofthe ~~that~~Securities ~~amount~~Act.

OnOur August 31, 2020, the Company closed the purchase of all of the assets of Pocono Coated Products (“PCP”) associated with its Transdermal, Topical, Cosmetic and Nutraceutical business (the “Assets”). pursuant to a Purchase Agreement (“Agreement”), entered into on August 31, 2020. The purchase price for the Assets was (i) $6,000,000 paid in shares of the Company’s common stock at a value of the average price of the previous 90 days at the date of Closing (the “Shares”); and (ii) a promissory note of the Company in the principal amount of $1,500,000, which note was repaid in full in October 2021. Subsequent to the repayment of the note, on October 25, 2021, the Shares were released from escrow.Business

OnAVERSA ~~October~~Abuse 5,Deterrent ~~2021,~~Transdermal the Company, having been approved for the listing of its common stock on The Nasdaq Capital Market effective October 1, 2021, consummated a public offering (the “IPO”) of units (the “Units”), of common stock and warrants that were offered in the IPO on The Nasdaq Capital Market, which included 1,231,200 (each a “Unit”), each Unit consisting of one share of common stock, par value $0.001 per share, and one warrant (each a “Warrant”) at a price of $5.36 per Unit. Each Warrant is immediately exercisable, entitles the holder to purchase one share of common stock at an exercise price of $6.43 and will expire five (5) years from the date of issuance. The underwriters’ over-allotment option was exercised for 184,800 warrants to purchase shares of common stock bringing the total net proceeds to the Company from the IPO to $5,836,230. The shares of common stock and Warrants were separately transferred immediately upon issuance. As of October 31, 2024, 457,794 Warrants issued in the IPO have been exercised, with net proceeds to the Company of $2,942,970.Products

26Our lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with our AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. We believe that our AVERSA technology can be broadly applied to various transdermal products, and our plan is to follow the development of AVERSA Fentanyl with the development of additional abuse deterrent transdermal products for pharmaceuticals that have a risk or history of abuse, misuse or accidental exposure. Specifically, we have expanded our development pipeline to include AVERSA Buprenorphine and AVERSA Methylphenidate. In addition, we are developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery.

OnIn ~~November~~January 12024, ~~2021,~~we ~~The~~signed ~~Board~~a ofcommercial ~~Directors adopted~~development ~~the 2021 Employee Stock Option Plan (the “Plan”). The Company has reserved 408,333 shares to issue~~ and ~~sell~~clinical ~~upon~~supply ~~the~~agreement ~~exercise of~~with ~~stock~~Kindeva ~~options~~Drug ~~issued under the Plan. On November 3~~Delivery, ~~2021,~~formerly ~~the~~3M ~~Company~~Drug ~~filed~~Delivery ~~a Registration Statement on Form S-8~~(“Kindeva”), tofor ~~register under~~ the ~~Securities~~development ~~Act~~ of ~~1933, as amended, the 408,333 shares of common stock reserved for issuance under the Plan, and on October 12, 2022,~~AVERSA aFentanyl ~~Post-Effective~~using ~~Amendment~~Kindeva’s ~~to the Form S~~FDA-8approved ~~was~~fentanyl ~~filed with the SEC~~patch. InThis ~~accordance~~agreement ~~with~~replaced the ~~Plan,~~previous onfeasibility ~~February~~agreement 1,between ~~2022,~~ the ~~Company reserved~~two ancompanies ~~additional~~which ~~233,333~~was ~~shares~~focused ~~and~~ on ~~February~~establishing ~~1, 2023,~~ the ~~Company~~feasibility ~~reserved~~of anincorporating ~~additional 233,333 shares. On March 20, 2024,~~ our ~~Board of~~AVERSA ~~Directors~~abuse ~~adopted~~deterrent antransdermal ~~amendment~~technology tointo ~~the Company~~Kindeva’s ~~2021 Employees Stock Option Plan (the “Plan”) increasing the~~ ~~number~~commercial oftransdermal ~~shares~~manufacturing ~~of common stock subject to the plan (as of March 20, 2024 875,000 shares) to 1,400,00 shares (the “Amendment”)~~process. ~~The~~ ~~plan adopted by the Board on November 1, 2021, provided for an initial 350,000 shares to issue and sell upon the exercise of stock options issued under the Plan.~~ The ~~Plan~~commercial ~~provides~~development for an automatic annual increase to be added on February 1 of each year equal to the lesser of (i) 250,000 shares of Common Equity or (ii) five percent (5%) of the total shares of Common Stock outstanding on such date (including for this purpose any shares of Common Stock issuable upon conversion of any outstanding capital equity of the Company) or (iii) such lesser number as determined by the Board. We will submit the Amendment to the Plan to our stockholders for adoption and ~~approval~~clinical atsupply ~~the~~agreement ~~2025 Annual Meeting. If the Amendment~~ is ~~not~~focused ~~approved~~on bydeveloping ~~stockholders within one year of adoption by~~ the ~~increase~~ ~~in shares subject to the Plan will be void, together with any options issued following March 20, 2024, in the period pending~~commercial ~~approval~~manufacturing ofprocess ~~the Plan by our stockholders. As of October 31, 2024, 75,166 shares remain available~~ for ~~issuance~~AVERSA ~~of options under the Plan~~Fentanyl.

~~The~~On ~~Company~~November ~~received~~1, a2021, ~~favorable~~The ~~verdict~~Board onof ~~July~~Directors adopted ~~13,~~the ~~2022~~2021 ~~from~~Employee ~~the~~Stock ~~Circuit~~Option ~~Court,~~Plan ~~Orange~~(the ~~County~~“Plan”), ~~Florida,~~and ~~providing~~the ~~for~~Plan ~~rescission~~then ofadopted ~~the~~provided ~~Company’s~~for ~~2017~~an ~~acquisition~~initial 350,000 ofshares ~~Advanced~~to ~~Health~~issue ~~Brands~~ and ~~recovery~~sell byupon the ~~Company~~exercise of ~~the 1,400,000 shares (adjusted for a 1-for-4 reverse~~ stock ~~split~~options ~~effective~~issued ~~June~~under ~~23, 2019 and~~ the ~~7-for-six~~Plan. ~~forward~~As ~~stock~~of ~~split~~May ~~effective~~30, ~~August 15~~2025, ~~2022)~~the ofCompany ~~common~~has ~~stock~~reserved ~~issued in the acquisition~~1,373,668 ~~effectively allowing the Company~~shares onto ~~July~~issue ~~25,~~and ~~2022~~sell toupon ~~cancel~~the ~~1.4M~~exercise ~~shares~~ of ~~common~~ stock ~~held~~options byissued under the ~~defendants~~Plan.

OnThe ~~July~~Plan ~~26,~~provides ~~2022,~~for ~~our~~an ~~Board~~automatic ofannual ~~Directors approved~~increase ~~the~~to ~~amendment~~be toadded ~~our~~on ~~Articles~~February 1 of ~~Incorporation~~each year equal to ~~effect~~the alesser 7of ~~for~~(i) 250,000 6shares ~~forward~~of ~~stock~~Common ~~split~~Equity or (ii) five percent (5%) of the ~~“Stock~~total ~~Split”)~~shares of ~~our~~Common Stock outstanding ~~common~~ ~~stock.~~on Wesuch ~~filed~~date ~~the~~(including ~~amendment~~for ~~set~~this ~~forth~~purpose inany ashares ~~Certificate~~ of ~~Change~~Common ~~with~~Stock ~~the~~issuable upon ~~Secretary~~conversion of ~~State~~any ofoutstanding ~~Nevada~~capital onequity ~~August~~of 4,the ~~2022.~~Company) ~~The 7:6~~or ~~forward~~(iii) such ~~split~~lesser ~~was~~number ~~effective~~as ~~for~~determined ~~trading~~by ~~purposes~~the onBoard. ~~the~~In ~~Nasdaq~~accordance with ~~Capital~~the ~~Market~~Plan, on ~~August~~February 121, 2022., ~~Each~~the ~~shareholder~~Company ofreserved ~~record~~an asadditional ~~of the~~233,333 ~~August~~shares ~~15,~~and ~~2022~~on ~~record~~February ~~date~~1, ~~received~~2023, ~~one~~the ~~(1)~~Company reserved an additional ~~share~~233,333 ofshares. ~~common~~On ~~stock~~March ~~for~~20, ~~each~~2024, ~~six~~our ~~(6)~~Board ~~shares~~of ~~held~~Directors asadopted ofan amendment to the ~~record~~Plan ~~date. No~~increasing ~~fractional~~the ~~shares~~number of shares of common stock ~~were~~subject ~~issued~~to inthe ~~connection~~Plan ~~with~~(as ~~the~~of ~~Stock~~March ~~Split.~~20, ~~Instead~~2024, ~~all~~875,000 shares) ~~were~~to ~~rounded~~1,400,00 upshares to (the ~~next whole share~~“Amendment”). InWe ~~connection~~submitted the ~~with~~Amendment to the ~~Stock~~Plan ~~Split,~~to ~~which~~our ~~did~~stockholders ~~not~~for ~~require~~adoption ~~shareholder~~and approval ~~under~~at the ~~Nevada~~2025 ~~corporation~~Annual ~~law~~Meeting, and the ~~number~~Amendment ofwas approved by ~~authorized~~a ~~shares~~majority vote of ~~common~~our ~~stock~~stockholders. As of ~~the~~May ~~Company~~30, ~~increased~~2025, inwith the ~~same~~February ~~ratio~~1, as2025 ~~the~~automatic ~~shares~~increase of ~~outstanding~~shares ~~common~~available ~~stock~~for ~~were increased~~issuance inunder the ~~Stock~~Plan, ~~Split~~276,333 ~~from~~shares ~~250,000,000~~remain ~~authorized~~available ~~shares~~for toissuance ~~291,666,666~~of ~~authorized~~options ~~shares~~under the Plan.

~~The~~On ~~Company~~April ~~on July 13~~19, ~~2023~~2024, ~~entered~~the ~~into~~Company completed an ~~amended three-year~~ $58,~~000~~400,000 ~~credit~~equity ~~line~~financing ~~facility~~with ~~(replacing~~European ~~the~~investors $of 2,~~000~~100,000 ~~facility~~units, ~~that~~at wea ~~had~~price ~~entered~~of ~~into~~$4.00 onper ~~March 19~~Unit, ~~2023),~~each ~~drawdowns~~Unit consisting of one ~~under~~share ~~which~~of ~~bear~~common ~~interest~~stock atand ~~the~~a ~~rate~~Warrant to purchase two shares of 7%common ~~per~~stock, ~~annum~~the Warrants having an initial exercise price of $6.43, are ~~The~~exercisable ~~credit~~by ~~line~~payment ~~provides~~of the ~~Company~~exercise ~~with~~price ~~available~~in ~~financing~~cash ~~through~~only and expire April 19, 2029, five years from the ~~FDA~~date ~~approval~~of issuance. The ~~process~~offering was made solely to investors resident outside the United States and ~~into~~was ~~commercial~~not ~~scale~~registered ~~manufacturing~~under the Securities Act, ~~for~~or the securities ~~Company’s~~laws ~~patented~~of ~~lead~~any ~~product~~jurisdiction, ~~AVERSA™~~including ~~Fentanyl~~any jurisdiction outside the United States, anbut ~~abuse-deterrent~~was made privately by the Company ~~fentanyl~~pursuant ~~transdermal~~to ~~system~~the exemptions from registration provided in the SEC’s Regulation S and other exemptions under the Securities Act.

On December 27, 2023, the Company issued 1,026,720 shares of common stock in conversion of the outstanding $2,000,000 principal amount, plus accrued interest for the Credit Line Note of the Company held TII Jet Services LDA; and on May 14, 2024, TII Jet Services agreed to convert an additional $300,000 of principal of the Credit Line Note plus accrued interest at a conversion price of $4.00 per share, in exchange for the issuance of 76,230 shares of common stock. The fair value of the common stock at the date of issuance was $3.71 per share, which resulted a gain on the settlement of debt of $22,109.23

On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors (the “Offering”) of 2,100,000 units (“Units”), at a price of $4.00 per Unit, each Unit consisting of one share of common stock (“Shares”) and a Warrant to purchase two Shares of common stock, the Warrants having an initial exercise price of $6.43, are exercisable by payment of the exercise price in cash only and expire April 19, 2029, five years from the date of issuance. The Offering was made solely to investors resident outside the United States and was not registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any jurisdiction, including any jurisdiction outside the United States, but was made privately by the Company pursuant to the exemptions from registration provided in the SEC’s Regulation S and other exemptions under the Securities Act.

Results of Operations

Three Months Ended ~~October~~April 3130, ~~2024~~2025 and ~~2023~~2024

For the three months ~~ended~~ending ~~October~~April 3130, ~~2024~~2025, we generated revenue of $~~645~~667,~~796~~432 and our revenue costs ofwere ~~revenue~~$415,451, ~~were~~resulting in a gross profit of $~~454~~251,~~767~~981. For the three months ~~ended~~ending April ~~October 31~~30, ~~2023~~2024, we generated revenue of $~~427~~408,~~841~~532 and our costs of revenue were $~~268~~243,~~920~~746, resulting in a gross profit of $164,786. Our revenue for ~~October~~the 31three months ending April 30, ~~2024~~2025, was derived from sales from ~~contract manufacturing services performed in~~ our Pocono Pharmaceuticals ~~(Active Intelligence)~~ segment and $-0- from contract research and development services from our 4P Therapeutics segment. The revenue from the ~~Transdermal~~Pocono ~~Patches~~Pharmaceuticals segment increased from the prior year as the Company ordered additional equipment to meet the new demand and implemented this equipment during the third quarter of the prior year. An increase in demand is expected in the balance of the current year. ~~The~~There ~~Company’s~~were ~~contract~~no ~~with~~sales ~~Sorrento~~in ~~Therapeutics~~our ~~was completed and~~ 4P Therapeutics ~~devoted~~segment ~~most~~in ~~of its time to~~ the ~~development~~current ofyear ~~its~~due ~~Aversa~~to ~~product.~~a ~~Our~~shift ~~cost~~in offocus ~~revenue~~and ~~for~~the ~~our~~main contract ~~research~~wound ~~and~~down ~~development~~in ~~services~~the ~~represents our~~prior ~~labor~~year. ~~cost~~The ~~plus~~increase ain ~~modest~~gross ~~amount~~margin ofis ~~material~~due ~~costs~~primarily to ~~which~~higher wemargins ~~passed~~in onour tosales ~~the client~~mix.

For the three months ~~ended~~ending ~~October~~April 3130, ~~2024~~2025, our selling, general and administrative expenses were $~~737~~982,~~102~~052, primarily legal, accounting and ~~administrative~~public ~~salaries~~relations ~~and non-cash compensation from the issuance of employee stock options~~ compared to $1,~~330~~079,~~929~~728 for the three months ~~ended~~ending ~~October~~April 3130, ~~2023~~2024. The decrease from ~~2023~~ 2024 is primarily attributable to decreases in ~~professional fees and~~ non-cash equity-based expenses.

During the three months ~~ended~~ending ~~October~~April 3130, ~~2024~~2025, the Company incurred research and development expenses of its Aversa Fentanyl product of $~~880~~683,~~768~~426, primarily of salaries and increases in development costs from Kindeva as compared to $~~551~~974,~~503~~535 for the three months ~~ended~~ending ~~October~~April 3130, ~~2023~~2024. The decrease is primarily attributable to a reduction in labor costs.

We incurred interest expenses of $45,~~031~~880 for the three months ~~ended~~ending ~~October~~April 3130, ~~2024~~2025, as compared to $408,~~200~~618 for the three months ~~ended~~ending ~~October~~April 3130, 2024. ~~The decrease is primarily due to the decrease in the Company’s related party loans.~~

Interest income for the three months ~~ended~~ending ~~October~~April 3130, ~~2024~~2025 was $6830,~~235~~508 as compared to $~~3,765~~18 for the three months ~~ended~~ending ~~October~~April 3130, ~~2023~~2024. The increase is primarily due to investment ~~of excess~~in excess cash from the Company’s equity financing.

As a result of the foregoing, we sustained a net loss of $1,~~362~~388,~~637~~869 or $(0.12) per share (basic and diluted) for the three months ~~ended~~ending ~~October~~April 3130, ~~2024~~2025, compared with a loss of $1,~~759~~898,~~940~~077, or $(0.2221) per share (basic and diluted) for the three months ~~ended~~ending ~~October~~April 3130, ~~2023~~2024.

Nine Months Ended October 31, 2024 and 2023

For the nine months ended October 31, 2024, we generated revenue of $1,497,158 and our costs of revenue were $1,039,785 resulting in a gross margin of $457,373. For the nine months ended October 31, 2023, we generated revenue of $1,560,701 and our costs of revenue were $879,824, resulting in a gross margin of $680,877. Our revenue for October 31, 2024, was derived from sales from our Transdermal Patches segment and $-0- from contract services from our 4P Therapeutics segment. The revenue from the Transdermal Patches segment decreased from the prior year. An increase in demand is expected in the subsequent quarter. Our cost of revenue for our contract research and development services represents our labor cost plus a modest amount of material costs which we passed on to the client. Our cost of sales decreased during the period for our contract services in comparison to the prior year as our main contract has been completed and the balance of the contract is being recognized with limited additional costs.

For the nine months ended October 31, 2024, our selling, general and administrative expenses were $2,554,155 primarily legal, accounting and non-cash compensation compared to $2,849,399 for the nine months ended October 31, 2023.The decrease from 2023 is primarily attributable to a decrease in investor relations expenses and professional fees.

During the nine months ended October 31, 2024, the Company incurred research and development expenses of its Aversa Fentanyl product of $ 2,629,278 primarily of salaries and increases in development costs from Kindeva as compared to $1,397,055 for the nine months ended October 31, 2023.

We incurred interest expense of $17,668 for the nine months ended October 31, 2024, as compared to $52,601 for the nine months ended October 31, 2023. The decrease is primarily due to the decrease in the Company’s related party debt.

Interest income for the nine months ended October 31, 2024 was $145,585 as compared to $13,830 for the nine months ended October 31, 2023. The increase is primarily due to the investment of excess cash from the Company’s equity financing.

During the nine months ended October 31, 2024, the Company incurred a loss on extinguishment of debt of $368,036 in connection with the issuance of common stock and warrants to a related party debtor.

As a result of the foregoing, we sustained a net loss of $4,966,179 or $0.48)per share (basic and diluted) for the nine months ended October 31, 2024 compared with a loss of $3,604,348, or $0.46 per share (basic and diluted) for the nine months ended October 31, 2023.

Liquidity and Capital Resources

As of ~~October~~April 3130, ~~2024~~2025, we had $52,~~698~~964,~~187~~097 in cash and cash equivalents and working capital of $42,~~943~~504,~~816~~596, as compared with cash and cash equivalents of $~~492~~4,~~942~~311,719 and working capital of $223,~~770~~811,420 as of January 31, ~~2024~~2025.

For the ~~nine~~three months ~~ended~~ending ~~October~~April 3130, ~~2024~~2025, we used cash of $31,~~387~~336,~~320~~972 in our operations. The principal adjustments to our net loss of $41,~~966~~388,~~179~~869 were depreciation and amortization of $~~212~~57,~~199~~490, and the issuance of employee stock ~~options and warrants~~ for services in the amount of $~~686~~63,~~685 and the loss on extinguishment of debt of $368,036~~850.

For the ~~nine~~three months ~~ended~~ending ~~October~~April 3130, ~~2024~~2025, we used cash in investing activities of $925,~~043~~324 primarily for the purchase of equipment.

For the ~~nine~~three months ~~ended~~ending ~~October~~April 3130, ~~2024~~2025, we ~~provided~~used cash in financing activities of $85,~~684,608~~326 primarily from the ~~proceeds~~payment of ~~$8,400,000~~note ~~from the sale of common stock and warrants and $300,000 from its line of credit~~payable.

Off Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Critical Accounting Policies

Going Concern Assessment

Management assesses liquidity and going concern uncertainty in the Company’s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the “look-forward period”, as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved and management has the proper authority to execute them within the look-forward period.

As of ~~October~~April 3130, ~~2024~~2025, the Company had cash and cash equivalents of $52,~~698~~904,~~187~~097 and working capital of $42,~~934~~504,~~816~~596. For the ~~nine~~three months ~~ended~~ending ~~October~~April 3130, ~~2024~~2025, the Company incurred a net loss from operations of $41,~~726~~413,~~060~~497 and used cash flow from operations of $31,~~387~~336,~~320~~972. The Company has generated operating losses ~~since~~ since its inception and has relied on sales of securities and the issuance of third-party and related-party debt to support cash flow from operations. The Company has used these proceeds to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three-year $2,000,000 Credit Line Note facility with a related party, amended on July 13, 2023, to $5,000,000, which will permit the Company to draw down on the credit line to fund the Company’s research and development of its Aversa product. On April 19, 2024, the Company received proceeds of $8,400,000 from an equity financing with European investors.

Management has prepared estimates of operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company’s ability to continue operations as a going concern.

Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.

Principles of Consolidation

The consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company’s financial statements from the date of acquisition of August 1, 2018, and the operations of Pocono and Active Intelligence are included in the Company’s financial statements from the date of acquisition of September 1, 2020, under Pocono Pharmaceuticals Inc. The wholly owned subsidiaries are as follows:

Nutriband Ltd.

4P Therapeutics LLC

Pocono Pharmaceuticals Inc.

Use of Estimates

Revenue Recognition

Revenue Types

The following is a description of the Company’s revenue types, which include professional services and sale of goods:

●

Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods.

● Product revenues are derived from the sale of the Company’s consumer transdermal, topical and tape products with sales listed under sale of goods.

●

Contract research and development services for pharmaceutical and medical devices for life sciences customers with revenues listed under services.

Contracts with Customers

Contract Liabilities

Performance Obligations

All revenue recognized in the income statement is considered to be revenue from contracts with customers.

Cash and cash equivalents.

Cash and cash equivalents include cash on hand, cash on deposit in money market accounts. The Company considers short-term highly liquid investments with an original maturity date of three months or less that are not part of an investment pool to be cash equivalents. As of ~~October~~April 3130, ~~2024~~2025, the Company had $52,~~171~~547,000 that exceeded federally insured limits.

Accounts receivable

Trade accounts receivables are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make the required payments. The Company determines its allowances by both specific identification of ~~customer~~ customer accounts where appropriate and the application of historical loss to non-applicable accounts. For the ~~nine~~three months ~~ended~~ending ~~October 31~~April 30, ~~2024~~2025, and ~~2023~~2024, the Company recorded bad debt expenses of $~~1,200~~-0- and $111,~~836~~200, respectively, for doubtful accounts related to accounts receivable. During the year ended January 31, 2024, the Company entered into an accounts receivable sale agreement for one of its subsidiaries. ~~The~~ The Company received $106,528 in funds against an account receivable that is currently a claim in bankruptcy. The net accounts receivable remain on the books of the Company and a corresponding amount has been included as a secured borrowing liability under Notes payable. As of ~~October~~April 3130, ~~2024~~2025, the receivable has been reserved in full. If the bankruptcy claim is not paid in full by the debtor, Company is obligated to pay any difference to the factor. The loan bears interest at 10%. The Company adopted ASU 2016-13 during 2013 and implemented the guidance on expected credit losses.

3127

Inventories

Inventories are valued at the lower of cost and reasonable value determined using the first-in, first-out (FIFO) method. ~~Net~~The net realized value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of ~~October~~April 3130, ~~2024~~2025, total inventory was $~~168~~215,~~299~~324, consisting of work-in-process of $31100,~~418~~690, finished goods of $~~966~~9,172 and raw materials of $~~135~~105,~~914~~463. As of January 31, ~~2024~~2025, total inventory was $~~168~~212,~~605~~041, consisting of work-in-process of $746,~~466~~235, finished goods of $816,~~707 and~~609 and raw materials of $~~134~~149,~~691~~177.

Property, Plant and Equipment

Lab Equipment		5-10 years
Furniture and fixtures		3 years
Machinery and equipment		10-20 years

Intangible Assets

Goodwill

Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company’s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $1,719,235. On August 31, 2020, in connection with the Company’s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $5,810,640. During the years ended January 31, ~~2024~~2025, and ~~2023~~2024, the Company recorded an impairment charge of $3,302,478-0- and $~~327~~-0-,~~326,~~ respectively, reducing the Active Intelligence LLC Goodwill to $~~3,302,478~~-0-. As of ~~October~~April 3130, ~~2024~~2025, and January 31, ~~2024~~2025, Goodwill amounted to $51,~~021~~719,~~713 and~~535 and $51,~~021~~719,~~713~~535, respectively.

Long-lived Assets

3228

Earnings per Share

Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of ~~October~~April 3130, ~~2024~~2025, and ~~2023~~2024, there were 6,~~922~~920,~~833~~641 and 26,~~157~~862,~~873~~308 common stock equivalents outstanding, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.

Stock-Based Compensation

Business Combinations

Leases

The Company applies guidance for right-of-use accounting for all leases and records the operating lease liabilities on its balance sheet. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.

Research and Development Expenses

Research and development costs are expensed as incurred.

Income Taxes

Taxes are calculated in accordance with taxation principles currently effective in the United States and Ireland.

The Company records net deferred tax assets to the extent they believe these assets will more likely than not be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. In the event the Company was todetermined ~~determine~~ that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure controls and procedures.

As of the end of period covered by this report, we carried out an evaluation, with the participation of our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures pursuant to Securities Exchange Act Rule 13a-15. Based upon that evaluation, we concluded that our disclosure controls and procedures are not effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

Management has determined that our internal controls contain material weaknesses due to the absence of segregation of duties, as well as lack of qualified accounting personnel, and excessive reliance on third-party consultants for accounting, financial reporting and related activities. During the past fiscal year, we have added qualified accounting personnel, so the Company does not have to rely on third-party consultants. The Company has established additional monitoring controls over the financial statements. We have also improved our internal controls to provide for a detailed accounting review of all revenue items and accounts receivable and accounts payable transactions in connection with the entry and categorization of each transaction in the preparation of the Company’s financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.

Changes in internal controls over financial reporting.

No changes were made to our internal controls in the quarterly period covered by this report that have materially affected, or are reasonably likely materially to affect, our internal control over financial reporting.

3430

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

With respect to legal proceedings that arise in the ordinary course of business, when the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated.

Currently, there are no pending hearings or motions, asand ~~both~~the ~~parties~~case ~~are~~is ~~engaged~~ in the discovery ~~and~~stage. ~~are~~In ~~attempting~~early to2024, ~~resolve~~ the ~~matter~~plaintiffs ~~amicably~~proposed a settlement offer of $100,000. The Company has not responded to that settlement offer.

ITEM 1A. RISK FACTORS

You should carefully consider the key risks described below together with all of the other information included in this report and our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on ~~May~~April 128, ~~2024~~2025, before making an investment decision with regard to our securities. The risks set ~~forth~~ forth below and in our Form 10-K are not the only risks facing us. Additional risks and uncertainties may exist that could also adversely ~~affect~~ affect our business, prospects or operations. If any of the following risks actually occurs, our business, financial condition or results of of operations could be harmed. In that case, the trading price of our common stock could decline, and you may lose all or a significant ~~part~~ part of your investment.

~~Because~~There weis ~~are an early-stage company with~~economic ~~minimal~~uncertainty ~~revenue~~concerning ~~and~~economic apolicies ~~history~~being ofpursued ~~losses~~by ~~and~~the wecurrent ~~expect~~administration toin ~~continue~~the toUnited ~~incur~~States ~~losses~~that ~~for~~may affect the ~~foreseeable~~costs ~~future,~~and timing weof ~~cannot~~the ~~assure~~process ~~you~~of ~~that we~~bringing ~~can~~our orproducts ~~will~~to bemarket ~~able~~through toapprovals ~~operate~~with ~~profitably~~the FDA.

WeOur ~~did~~operating ~~not~~results could ~~generate~~be ~~any~~affected ~~revenue~~by ~~prior to~~ the ~~quarter ended~~current ~~October~~political ~~31,~~and ~~2018~~economic ~~and,~~uncertainties ~~since~~related ~~then,~~to wethe ~~have~~economy ~~reported~~of ~~only~~the ~~modest~~United ~~revenue~~States, ~~from~~the ~~our~~domestic pharmaceutical industry ~~transdermal~~and ~~patch~~world ~~business~~economies. WeFuture ~~are subject~~conditions tomay ~~the~~also ~~risks~~adversely ~~common~~affect toour ~~start-up,~~pricing ~~pre-revenue enterprises~~strategy, ~~including,~~promotional ~~among~~activities ~~other~~and ~~factors,~~our ~~undercapitalization, cash shortages,~~profitability ~~limitations~~and ~~with~~margins. ~~respect to personnel~~Additionally, ~~financial~~many ~~and~~of ~~other~~the ~~resources~~effects and ~~lack~~consequences of ~~revenues~~U.S. ~~Drug~~and ~~development~~global ~~companies~~financial ~~typically~~and ~~incur substantial~~economic ~~losses~~conditions ~~during~~could ~~the~~potentially have ~~product~~a ~~development~~material ~~and~~adverse ~~FDA~~effect ~~testing~~on ~~phase~~our ofliquidity ~~the business~~ and docapital ~~not~~resources, ~~generate~~including ~~revenues until after~~ the ~~drug has~~ability ~~received~~to ~~FDA~~raise ~~approval~~additional capital, ~~which~~if ~~cannot be assured~~needed, ~~and~~or could ~~until~~otherwise ~~the~~negatively ~~company~~affect ~~has~~our ~~started~~business toand ~~sell~~financial ~~the product~~results. WeMarket ~~can~~instability ~~give~~could nomake ~~assurance~~it ~~that we~~more ~~can~~difficult orfor ~~will~~us ~~ever be successful in achieving profitability~~ and ~~the likelihood of~~ our ~~success~~suppliers to ~~must~~accurately beforecast ~~considered~~future inproduct ~~light~~demand ~~of our early stage of operations~~trends. WeAdditionally, ~~cannot~~inflationary ~~assure~~factors ~~you~~such ~~that~~as weincreases ~~will~~in bethe ~~able~~costs to ~~operate~~purchase ~~profitably or generate positive cash flow. If we cannot achieve profitability~~products, acquire weproduct ~~may~~rights ~~be forced to cease operations~~ and ~~you~~overhead costs may ~~suffer~~adversely aaffect ~~total~~our ~~loss~~operating ~~of your investment~~results.

35In this economic environment, we are also subject to the risks common to low-revenue start-up enterprises, including, among other factors, undercapitalization, cash shortages, limitations with respect to personnel, financial and other capital or operating expenditures. Drug development companies typically incur substantial losses during the product development and FDA testing phase of the business and do not generate revenues until after the drug has received FDA approval, which cannot be assured, and until the company has started to sell the product. We can give no assurance that we can or will ever be successful in achieving profitability and the likelihood of our success must be considered in light of our early stage of operations. We cannot assure you that we will be able to operate profitably or generate positive cash flow. If we cannot achieve profitability, we may be forced to cease operations and you may suffer a total loss of your investment.

Because we do not have a product we can market in the United States, we cannot predict when or whether we will operate profitably.

We have not completed the development of our lead product, which is our abuse deterrent fentanyl transdermal system, and we do not have any product that we can market in the United States. Because of the numerous risks and uncertainties associated with product development, we cannot assure you that we will be able to develop and market any products or achieve or attain profitability. If we are able to obtain financing for our operations, we expect that we will incur substantial expenses as we continue with our product development and clinical trials. Further, if we are required by applicable regulatory authorities, including the FDA as well as the comparable regulatory agencies in other countries in which we may seek to market product, to perform studies in addition to those we currently anticipate, our expenses will increase beyond expectations and the timing of any potential product approval may be delayed. As a result, we ~~expect~~could to continue to incur substantial losses and negative cash flow as ~~for~~long ~~the~~as ~~foreseeable~~these ~~future~~negative factors continue in effect.

IfA ~~any~~number of ~~our~~ ~~potential~~factors, ~~products~~including, ~~are approved for marketing~~ but ~~fail~~not limited to ~~achieve~~ the ~~broad~~following, ~~degree~~may affect ofour ~~physician~~ability orto ~~market~~develop ~~acceptance necessary for commercial success,~~ our ~~operating~~business ~~results~~ and ~~financial~~operate ~~condition will be adversely affected.~~profitably:

If● ~~any of the products in~~ our ~~pipeline~~ability ~~receives FDA approval thereby allowing us~~ to ~~market~~obtain ~~the product in the United States, it will be~~ necessary ~~for~~funding us to generate acceptance of our product for the indications covered by the FDA approval. In order to generate acceptance in the marketplace, we will need to demonstrate to physicians, patients and payors that our product provides a distinct advantage or better outcome at a price that reflects the value of our product as compared with existing products. We will need to develop and implement a marketing program directed at both physicians and the general public. Since we do not presently have the resources necessary to develop or implement an in-house marketing program and we may not have the funds to do so if and when we obtain FDA approval to market our ~~product,~~proposed we will need to establish a distribution network though license and distribution agreements with third parties who have the capability to market our product to physicians, and we will be dependent upon the ability of these third parties to market our products effectively. We cannot assure you that we will be able to negotiate license and distribution agreements with terms that are acceptable to us. Since we do not have an established track record and our product pipeline is relatively small, we may be at a disadvantage in negotiating the terms of license and distribution agreements. Further, we may have little control over the development and implementation of our licensee’s marketing program, and our licensees may have interests that are inconsistent with ours with respect to the allocation of resources and implementation of the marketing program. We cannot assure you that a marketing program for any of our products can or will be implemented effectively or that we will be successful in developing physician and emergency service acceptance of our products.;

~~The~~● ~~drug~~the ~~delivery industry~~success isof ~~subject~~clinical totrials ~~rapid~~for ~~technological change and,~~ our ~~failure to keep up with technological developments may impair our ability to market our~~ products.;

Our products use technology which we developed for the transdermal delivery of drugs. The field of drug delivery is subject to rapid technological changes. Our future success will depend upon our ability to keep abreast of the latest developments in the industry and to keep pace with advances in technology and changing customer requirements. If we cannot keep pace with such changes and advances, our proposed products could be rendered obsolete, which would result in our having to cease its operations.31

If● weour ability to obtain FDA approval, wefor ~~will~~us ~~face~~to ~~significant~~market ~~competition~~any ~~from~~proposed ~~better~~product ~~known~~in ~~and~~our ~~better~~pipeline ~~capitalized~~in ~~companies.~~the United States;

If● ~~we obtain FDA approval for~~ any ofdelays ~~our~~in ~~products,~~regulatory wereview ~~expect to face significant competition from existing companies, which are better known~~ and ~~already~~approval ~~have~~of ~~developed relationships with physicians within the healthcare system. Any~~ product we may develop will compete with existing medications performing the same medicinal functions, which may include transdermal patches. We cannot assure you that we will be able to compete successfully. In addition, even if we are able to commercialize our product candidates, we may not be able to price them competitively with current standard of care products or their price may drop considerably due to factors outside our control. If this happens or the price of materials and manufacture increases dramatically, our ability to continue to operate our business would be materially harmed and we may be unable to commercialize any products successfully. In addition, other pharmaceutical companies may be engaged in developing, patenting, manufacturing and marketing products that compete with those that we are developing. These potential competitors may include large and experienced companies that enjoy significant competitive advantages over us, such as greater financial, research and development~~, manufacturing, personnel and marketing resources, greater brand recognition and more experience and expertise in obtaining marketing approvals from the FDA and foreign regulatory authorities.~~;

36● if we obtain FDA approval to market our product, our ability to establish manufacturing and distribution operations or entering into manufacturing and distribution agreements with qualified third parties;

●

market acceptance of our products;

●

our ability to establish an effective sales and marketing infrastructure;

●

our ability to protect our intellectual property;

●

competition from existing products or new products that may emerge;

●

potential product liability claims and adverse events;

●

our ability to adequately support future growth; and

●

our ability to attract and retain key personnel to manage our business effectively.

Our stock price has been and is likely to continue to be volatile and you may not be able to resell shares of our common stock at or above the price you paid, if at all.

The trading price of our common stock has experienced fluctuations due to the factors discussed in these risk factors ~~section and elsewhere in this report~~. In addition, the stock market in general has, and the NASDAQ ~~Global~~Capital Market and technology companies in particular have, experienced extreme price and volume fluctuations. These trading prices and valuations may not be sustainable. These broad market and industry factors may decrease the market price of our common stock, regardless of our actual operating performance. In addition, in the past, following periods of volatility in the overall market and the market price of a company’s securities, securities class action litigation has often been instituted against companies (primarily those that are larger than us) that experienced such volatility. This type of litigation, if instituted against us, regardless of its outcome, could result in substantial costs and a diversion of our management’s attention and resources.

~~Our~~Stockholders ~~business~~may isexperience ~~impacted~~significant dilution byas ~~the~~a ~~following~~result ~~additional key~~of ~~risks:~~future equity offerings and other issuances of our common stock or other securities.

●We ~~The~~will ~~FDA~~need ~~regulatory~~to ~~process~~raise substantial funds in order to develop our products. In order to raise additional capital, we may ~~take~~in ~~longer~~the ~~and~~future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may be ~~more~~based ~~expensive~~on ~~than~~a wediscount ~~anticipate~~from ~~without~~market at the time of issuance. Stockholders will incur dilution upon exercise of any ~~assurance~~outstanding stock options, warrants or upon the issuance of shares of common stock under our present and future stock incentive programs. In addition, the sale of shares and any future sales of a substantial number of shares of our common stock in the public market, or the perception that wesuch sales may occur, could adversely affect the price of our common stock. We cannot predict the effect, if any, that market sales of those shares of common stock or the availability of those shares of common stock for sale will ~~obtain~~have ~~FDA~~on ~~approval~~the market price of our common stock.

●The Ifdrug wedelivery ~~are~~industry ~~not~~is ~~able~~subject to rapid ~~obtain~~technological ~~FDA~~change, ~~approval~~and ~~for~~ our ~~lead~~failure ~~product, we may not have the resources~~ to ~~develop~~keep ~~any~~up ~~other~~with ~~product,~~technological ~~and~~developments we may ~~not~~impair beour ~~able~~ability to ~~continue~~market inour ~~business~~products.

●Our Weproducts ~~may~~use ~~not~~technology bewhich ~~able~~we developed for the transdermal delivery of drugs. The field of drug delivery is subject to ~~launch~~rapid ~~any~~technological changes. Our future success will depend upon our ability to keep abreast of the latest developments in the industry and to keep pace with advances in technology and changing customer requirements. If we cannot keep pace with such changes and advances, our proposed products ~~for~~could be rendered obsolete, which would weresult ~~receive~~in ~~FDA~~our ~~marketing~~having ~~approval~~to cease its operations.

● We may not be able to establish a distribution network for the marketing and sale of any products for which we receive FDA approval.

● We may not be able to establish manufacturing facilities in compliance with FDA good manufacturing practices or to enter into manufacturing agreements for the manufacture of our products in an FDA approved manufacturing facility.

● It may be necessary to us to enter into a joint venture or other strategic relationship in order to develop, perform clinical testing for, manufacture or market any of our proposed products. We may not be able to enter into such a relationship, and any relationship may not be successful, and the other party may have business interests and priorities that are different from ours.

● We may be unable to accurately estimate anticipated expenses, capital requirements and needs for additional financing;

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Issuer Purchases of Equity Securities9

In November 2024, the Company purchased 20,400 shares of its common stock for $99,046 and recorded the purchase as Treasury Stock as of December 2, 2024.

Period		(a) Total number of shares of common stock purchased				(b) Average price paid per share				(c) Total number of shares purchased as part of publicly announced plans or programs				(d) Maximum number (or approximate dollar value) of shares that may yet to be purchased under the plans or programs
November 1 to December 2, 2024			20,400			$	4.85				20,400			$	900,954

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure controls and procedures.

Changes in internal controls over financial reporting.

ITEM 6. EXHIBITS.

Exhibit Number		Description of Exhibits
31.1		Section 302 Certification of Chief ~~Executivr~~Executive Officer.
31.2		Section 302 Certification of Chief Financial Officer.
32.1		Section 906 Certification of Chief Executive Officer.
32.2		Section 906 Certification of Chief Financial Officer.
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

3932

SIGNATURES

In accordance with the requirements of the Exchange Act, the Company has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NUTRIBAND INC.
December 3, 2024	By:	/s/ Gareth Sheridan
May 30, 2025	By:	/s/ Gareth Sheridan
		Gareth Sheridan, Chief Executive Officer
		(Principal Executive Officer)
December 3, 2024	By:	/s/ Gerald Goodman
May 30, 2025	By:	/s/ Gerald Goodman
		Gerald Goodman, Chief Financial Officer
		(Principal Financial Officer)

4033

NV 0 false --01-31 Q3 2025 0001676047 0001676047 2024-02-01 2024-10-31 0001676047 us-gaap:CommonStockMember 2024-02-01 2024-10-31 0001676047 ntrb:WarrantsMember 2024-02-01 2024-10-31 0001676047 2024-12-02 0001676047 2024-10-31 0001676047 2024-01-31 0001676047 2024-08-01 2024-10-31 0001676047 2023-08-01 2023-10-31 0001676047 2023-02-01 2023-10-31 0001676047 us-gaap:CommonStockMember 2024-01-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2024-01-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-31 0001676047 us-gaap:RetainedEarningsMember 2024-01-31 0001676047 us-gaap:TreasuryStockCommonMember 2024-01-31 0001676047 us-gaap:CommonStockMember 2024-02-01 2024-10-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2024-02-01 2024-10-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-02-01 2024-10-31 0001676047 us-gaap:RetainedEarningsMember 2024-02-01 2024-10-31 0001676047 us-gaap:TreasuryStockCommonMember 2024-02-01 2024-10-31 0001676047 us-gaap:CommonStockMember 2024-10-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2024-10-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-10-31 0001676047 us-gaap:RetainedEarningsMember 2024-10-31 0001676047 us-gaap:TreasuryStockCommonMember 2024-10-31 0001676047 2023-01-31 0001676047 us-gaap:CommonStockMember 2023-01-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2023-01-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-31 0001676047 us-gaap:RetainedEarningsMember 2023-01-31 0001676047 us-gaap:TreasuryStockCommonMember 2023-01-31 0001676047 us-gaap:CommonStockMember 2023-02-01 2023-10-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2023-02-01 2023-10-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-02-01 2023-10-31 0001676047 us-gaap:RetainedEarningsMember 2023-02-01 2023-10-31 0001676047 us-gaap:TreasuryStockCommonMember 2023-02-01 2023-10-31 0001676047 2023-10-31 0001676047 us-gaap:CommonStockMember 2023-10-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2023-10-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-10-31 0001676047 us-gaap:RetainedEarningsMember 2023-10-31 0001676047 us-gaap:TreasuryStockCommonMember 2023-10-31 0001676047 2024-07-31 0001676047 us-gaap:CommonStockMember 2024-07-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2024-07-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-31 0001676047 us-gaap:RetainedEarningsMember 2024-07-31 0001676047 us-gaap:TreasuryStockCommonMember 2024-07-31 0001676047 us-gaap:CommonStockMember 2024-08-01 2024-10-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2024-08-01 2024-10-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-08-01 2024-10-31 0001676047 us-gaap:RetainedEarningsMember 2024-08-01 2024-10-31 0001676047 us-gaap:TreasuryStockCommonMember 2024-08-01 2024-10-31 0001676047 2023-07-31 0001676047 us-gaap:CommonStockMember 2023-07-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2023-07-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-31 0001676047 us-gaap:RetainedEarningsMember 2023-07-31 0001676047 us-gaap:TreasuryStockCommonMember 2023-07-31 0001676047 us-gaap:CommonStockMember 2023-08-01 2023-10-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2023-08-01 2023-10-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-08-01 2023-10-31 0001676047 us-gaap:RetainedEarningsMember 2023-08-01 2023-10-31 0001676047 us-gaap:TreasuryStockCommonMember 2023-08-01 2023-10-31 0001676047 ntrb:FourPTherapeuticsLLCMember 2018-08-01 0001676047 us-gaap:CommonStockMember 2018-08-01 0001676047 srt:MaximumMember 2018-08-01 0001676047 srt:MinimumMember 2018-08-01 0001676047 2018-08-01 0001676047 ntrb:PoconoPharmaceuticalsMember 2024-10-31 0001676047 us-gaap:RelatedPartyMember 2023-03-31 0001676047 ntrb:CreditLineNoteFacilityMember 2023-07-13 0001676047 2024-04-19 2024-04-19 0001676047 ntrb:LoanMember 2024-02-01 2024-10-31 0001676047 srt:MinimumMember 2024-10-31 0001676047 srt:MaximumMember 2024-10-31 0001676047 ntrb:FourPTherapeuticsLLCMember 2024-10-31 0001676047 ntrb:PoconoCoatedProductsLLCAndActiveIntelligenceLLCMember 2020-08-31 0001676047 ntrb:IntelligenceLLCMember 2024-02-01 2024-10-31 0001676047 ntrb:IntelligenceLLCMember 2022-02-01 2023-01-31 0001676047 ntrb:SaleOfGoodsMember 2024-02-01 2024-10-31 0001676047 ntrb:SaleOfGoodsMember 2023-02-01 2023-10-31 0001676047 ntrb:SaleOfGoodsMember 2024-08-01 2024-10-31 0001676047 ntrb:SaleOfGoodsMember 2023-08-01 2023-10-31 0001676047 us-gaap:ServiceMember 2024-02-01 2024-10-31 0001676047 us-gaap:ServiceMember 2023-02-01 2023-10-31 0001676047 us-gaap:ServiceMember 2024-08-01 2024-10-31 0001676047 us-gaap:ServiceMember 2023-08-01 2023-10-31 0001676047 country:US 2024-02-01 2024-10-31 0001676047 country:US 2023-02-01 2023-10-31 0001676047 country:US 2024-08-01 2024-10-31 0001676047 country:US 2023-08-01 2023-10-31 0001676047 ntrb:ForeignMember 2024-02-01 2024-10-31 0001676047 ntrb:ForeignMember 2023-02-01 2023-10-31 0001676047 ntrb:ForeignMember 2024-08-01 2024-10-31 0001676047 ntrb:ForeignMember 2023-08-01 2023-10-31 0001676047 srt:MinimumMember us-gaap:EquipmentMember 2024-10-31 0001676047 srt:MaximumMember us-gaap:EquipmentMember 2024-10-31 0001676047 us-gaap:FurnitureAndFixturesMember 2024-10-31 0001676047 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2024-10-31 0001676047 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2024-10-31 0001676047 us-gaap:EquipmentMember 2024-10-31 0001676047 us-gaap:EquipmentMember 2024-01-31 0001676047 us-gaap:MachineryAndEquipmentMember 2024-10-31 0001676047 us-gaap:MachineryAndEquipmentMember 2024-01-31 0001676047 us-gaap:FurnitureAndFixturesMember 2024-01-31 0001676047 us-gaap:LineOfCreditMember 2024-10-31 0001676047 us-gaap:LineOfCreditMember 2024-02-01 2024-10-31 0001676047 us-gaap:LoansPayableMember 2024-10-31 0001676047 us-gaap:LoansPayableMember 2024-01-31 0001676047 2022-04-03 0001676047 ntrb:AutomobileMember 2022-04-03 2022-04-03 0001676047 us-gaap:NotesPayableOtherPayablesMember 2024-10-31 0001676047 us-gaap:NotesPayableOtherPayablesMember 2024-01-31 0001676047 2023-07-17 0001676047 2024-05-15 2024-05-15 0001676047 ntrb:CreditLineNoteAgreementMember 2024-02-01 2024-10-31 0001676047 us-gaap:CommonStockMember 2024-10-31 0001676047 us-gaap:ConvertibleDebtMember 2024-02-01 2024-10-31 0001676047 us-gaap:NotesPayableOtherPayablesMember 2023-07-17 0001676047 2023-07-17 2023-07-17 0001676047 us-gaap:RelatedPartyMember us-gaap:LoansPayableMember 2024-10-31 0001676047 us-gaap:RelatedPartyMember 2024-02-01 2024-10-31 0001676047 ntrb:SecuredBorrowingLiabilityMember 2024-02-01 2024-10-31 0001676047 ntrb:CustomerBaseMember 2024-10-31 0001676047 ntrb:CustomerBaseMember 2024-01-31 0001676047 ntrb:IntellectualPropertyAndTrademarksMember 2024-10-31 0001676047 ntrb:IntellectualPropertyAndTrademarksMember 2024-01-31 0001676047 srt:ChiefExecutiveOfficerMember 2024-02-01 2024-10-31 0001676047 srt:ChiefExecutiveOfficerMember 2024-10-31 0001676047 ntrb:EmployeesMember 2024-10-31 0001676047 ntrb:EuropeanInvestorsMember 2024-04-19 2024-04-19 0001676047 ntrb:TIIJetServicesLDAMember 2024-02-01 2024-10-31 0001676047 2024-05-15 0001676047 srt:ChiefFinancialOfficerMember 2024-06-05 0001676047 2024-06-05 2024-06-05 0001676047 us-gaap:StockOptionMember 2023-02-01 2023-02-01 0001676047 us-gaap:StockOptionMember 2023-02-01 0001676047 us-gaap:StockOptionMember 2024-02-01 2024-10-31 0001676047 us-gaap:StockOptionMember 2023-02-01 2023-10-31 0001676047 ntrb:TIIJetServicesLDAMember 2023-07-17 0001676047 srt:ExecutiveOfficerMember 2023-09-30 2023-09-30 0001676047 srt:DirectorMember 2023-02-01 2023-10-31 0001676047 srt:MinimumMember srt:ExecutiveOfficerMember 2023-09-30 0001676047 srt:MinimumMember srt:ExecutiveOfficerMember 2023-10-31 0001676047 srt:MaximumMember srt:ExecutiveOfficerMember 2023-09-30 0001676047 srt:MaximumMember srt:ExecutiveOfficerMember 2023-10-31 0001676047 srt:DirectorMember 2023-09-30 0001676047 srt:DirectorMember 2023-10-31 0001676047 srt:ChiefFinancialOfficerMember us-gaap:WarrantMember 2023-02-01 2023-10-31 0001676047 srt:ChiefFinancialOfficerMember 2023-10-31 0001676047 us-gaap:WarrantMember 2023-02-01 2023-10-31 0001676047 us-gaap:PreferredStockMember 2016-01-15 0001676047 us-gaap:SeriesAPreferredStockMember 2019-05-24 0001676047 us-gaap:SeriesAPreferredStockMember 2019-06-20 0001676047 2019-06-25 2019-06-25 0001676047 srt:MaximumMember us-gaap:CommonStockMember 2019-06-25 0001676047 srt:MinimumMember us-gaap:CommonStockMember 2019-06-25 0001676047 srt:MinimumMember us-gaap:CommonStockMember 2020-01-27 0001676047 srt:MaximumMember us-gaap:CommonStockMember 2020-01-27 0001676047 srt:MinimumMember 2022-08-04 0001676047 srt:MaximumMember 2022-08-04 0001676047 us-gaap:TreasuryStockCommonMember 2024-09-10 2024-09-10 0001676047 us-gaap:IPOMember 2024-04-19 2024-04-19 0001676047 us-gaap:CommonStockMember 2024-04-19 0001676047 2024-04-19 0001676047 us-gaap:CommonStockMember 2024-04-19 2024-04-19 0001676047 ntrb:Warrants1Member 2024-04-19 0001676047 us-gaap:CommonStockMember 2024-05-15 0001676047 us-gaap:CommonStockMember 2024-05-15 2024-05-15 0001676047 us-gaap:CommonStockMember 2024-06-05 2024-06-05 0001676047 2023-10-31 2023-10-31 0001676047 us-gaap:WarrantMember ntrb:BarandnicHoldingsLtdMember 2023-03-07 0001676047 us-gaap:WarrantMember ntrb:BarandnicHoldingsLtdMember 2023-03-07 2023-03-07 0001676047 us-gaap:WarrantMember 2023-10-27 0001676047 srt:ChiefExecutiveOfficerMember 2023-10-27 0001676047 us-gaap:WarrantMember ntrb:BarandnicHoldingsLtdMember 2024-10-31 0001676047 us-gaap:WarrantMember ntrb:BarandnicHoldingsLtdMember 2024-02-01 2024-10-31 0001676047 srt:MinimumMember ntrb:BarandnicHoldingsLtdMember 2024-02-01 2024-10-31 0001676047 srt:MaximumMember ntrb:BarandnicHoldingsLtdMember 2024-02-01 2024-10-31 0001676047 srt:MaximumMember us-gaap:WarrantMember ntrb:BarandnicHoldingsLtdMember 2024-02-01 2024-10-31 0001676047 us-gaap:WarrantMember ntrb:BarandnicHoldingsLtdMember 2023-02-01 2024-01-31 0001676047 us-gaap:WarrantMember 2024-04-19 0001676047 us-gaap:WarrantMember 2024-04-19 2024-04-19 0001676047 us-gaap:WarrantMember 2024-05-15 0001676047 us-gaap:WarrantMember 2024-05-15 2024-05-15 0001676047 us-gaap:WarrantMember 2024-06-05 2024-06-05 0001676047 2024-06-05 0001676047 us-gaap:WarrantMember 2024-09-10 0001676047 us-gaap:WarrantMember 2024-09-10 2024-09-10 0001676047 2024-09-10 2024-09-10 0001676047 us-gaap:WarrantMember 2024-02-01 2024-10-31 0001676047 srt:MinimumMember us-gaap:WarrantMember 2024-02-01 2024-10-31 0001676047 srt:MaximumMember us-gaap:WarrantMember 2024-02-01 2024-10-31 0001676047 2021-11-01 2021-11-01 0001676047 2022-02-01 2022-02-01 0001676047 2023-02-01 2023-02-01 0001676047 2021-11-03 2021-11-03 0001676047 2024-03-20 0001676047 srt:MinimumMember srt:ChiefExecutiveOfficerMember 2024-10-31 0001676047 srt:MaximumMember srt:ChiefExecutiveOfficerMember 2024-10-31 0001676047 srt:MinimumMember 2024-02-01 2024-10-31 0001676047 srt:MaximumMember 2024-02-01 2024-10-31 0001676047 srt:ChiefExecutiveOfficerMember 2023-02-01 2024-01-31 0001676047 srt:MinimumMember srt:ChiefExecutiveOfficerMember 2024-01-31 0001676047 srt:MaximumMember srt:ChiefExecutiveOfficerMember 2024-01-31 0001676047 2023-02-01 2024-01-31 0001676047 srt:MinimumMember 2023-02-01 2024-01-31 0001676047 srt:MaximumMember 2023-02-01 2024-01-31 0001676047 us-gaap:WarrantMember 2023-01-31 0001676047 us-gaap:WarrantMember 2023-01-31 2023-01-31 0001676047 us-gaap:WarrantMember 2023-02-01 2024-01-31 0001676047 us-gaap:WarrantMember 2024-01-31 0001676047 us-gaap:WarrantMember 2024-10-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesOneMember 2024-10-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesOneMember 2024-02-01 2024-10-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesTwoMember 2024-10-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesTwoMember 2024-02-01 2024-10-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesThreeMember 2024-10-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesThreeMember 2024-02-01 2024-10-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesFourMember 2024-10-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesFourMember 2024-02-01 2024-10-31 0001676047 us-gaap:EmployeeStockOptionMember 2023-01-31 0001676047 us-gaap:EmployeeStockOptionMember 2023-01-31 2023-01-31 0001676047 us-gaap:EmployeeStockOptionMember 2023-02-01 2024-01-31 0001676047 us-gaap:EmployeeStockOptionMember 2024-01-31 0001676047 us-gaap:EmployeeStockOptionMember 2024-02-01 2024-10-31 0001676047 us-gaap:EmployeeStockOptionMember 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesOneMember 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesOneMember 2024-02-01 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwoMember 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwoMember 2024-02-01 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThreeMember 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThreeMember 2024-02-01 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFourMember 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFourMember 2024-02-01 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFiveMember 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFiveMember 2024-02-01 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSixMember 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSixMember 2024-02-01 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSevenMember 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSevenMember 2024-02-01 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesEightMember 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesEightMember 2024-02-01 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesNineMember 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesNineMember 2024-02-01 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTenMember 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTenMember 2024-02-01 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesElevenMember 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesElevenMember 2024-02-01 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwelveMember 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwelveMember 2024-02-01 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThirteenMember 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThirteenMember 2024-02-01 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFourteenMember 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFourteenMember 2024-02-01 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFifteenMember 2024-10-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFifteenMember 2024-02-01 2024-10-31 0001676047 us-gaap:StockOptionMember 2024-10-31 0001676047 us-gaap:StockOptionMember 2024-02-01 2024-10-31 0001676047 ntrb:PoconoPharmaceuticalsMember 2024-02-01 2024-10-31 0001676047 ntrb:PoconoPharmaceuticalsMember 2023-02-01 2023-10-31 0001676047 ntrb:PoconoPharmaceuticalsMember 2024-08-01 2024-10-31 0001676047 ntrb:PoconoPharmaceuticalsMember 2023-08-01 2023-10-31 0001676047 ntrb:FourPTherapeuticsMember 2024-02-01 2024-10-31 0001676047 ntrb:FourPTherapeuticsMember 2023-02-01 2023-10-31 0001676047 ntrb:FourPTherapeuticsMember 2024-08-01 2024-10-31 0001676047 ntrb:FourPTherapeuticsMember 2023-08-01 2023-10-31 0001676047 us-gaap:CorporateAndOtherMember 2024-02-01 2024-10-31 0001676047 us-gaap:CorporateAndOtherMember 2023-02-01 2023-10-31 0001676047 us-gaap:CorporateAndOtherMember 2024-08-01 2024-10-31 0001676047 us-gaap:CorporateAndOtherMember 2023-08-01 2023-10-31 0001676047 ntrb:ResearchAndDevelopment4PTherapeuticsMember 2024-02-01 2024-10-31 0001676047 ntrb:ResearchAndDevelopment4PTherapeuticsMember 2023-02-01 2023-10-31 0001676047 ntrb:ResearchAndDevelopment4PTherapeuticsMember 2024-08-01 2024-10-31 0001676047 ntrb:ResearchAndDevelopment4PTherapeuticsMember 2023-08-01 2023-10-31 0001676047 us-gaap:NonUsMember 2024-02-01 2024-10-31 0001676047 us-gaap:NonUsMember 2023-02-01 2023-10-31 0001676047 us-gaap:NonUsMember 2024-08-01 2024-10-31 0001676047 us-gaap:NonUsMember 2023-08-01 2023-10-31 0001676047 country:US 2024-10-31 0001676047 country:US 2024-01-31 0001676047 us-gaap:NonUsMember 2024-10-31 0001676047 us-gaap:NonUsMember 2024-01-31 0001676047 us-gaap:CorporateAndOtherMember 2024-10-31 0001676047 us-gaap:CorporateAndOtherMember 2024-01-31 0001676047 ntrb:PoconoPharmaceuticalsMember 2024-10-31 0001676047 ntrb:PoconoPharmaceuticalsMember 2024-01-31 0001676047 ntrb:FourPTherapeuticsMember 2024-10-31 0001676047 ntrb:FourPTherapeuticsMember 2024-01-31 0001676047 2022-07-31 0001676047 ntrb:MrGoodmanMember 2022-07-31 0001676047 2022-02-01 0001676047 2023-07-25 2023-07-25 0001676047 ntrb:SorrentoTherapeuticsIncMember 2024-01-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure utr:sqft

NV 0 0001676047 false 2026 Q1 --01-31 0001676047 2025-02-01 2025-04-30 0001676047 us-gaap:CommonStockMember 2025-02-01 2025-04-30 0001676047 ntrb:WarrantsMember 2025-02-01 2025-04-30 0001676047 2025-05-30 0001676047 2025-04-30 0001676047 2025-01-31 0001676047 2024-02-01 2024-04-30 0001676047 us-gaap:CommonStockMember 2025-01-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2025-01-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-31 0001676047 us-gaap:RetainedEarningsMember 2025-01-31 0001676047 us-gaap:TreasuryStockCommonMember 2025-01-31 0001676047 us-gaap:CommonStockMember 2025-02-01 2025-04-30 0001676047 us-gaap:AdditionalPaidInCapitalMember 2025-02-01 2025-04-30 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-02-01 2025-04-30 0001676047 us-gaap:RetainedEarningsMember 2025-02-01 2025-04-30 0001676047 us-gaap:TreasuryStockCommonMember 2025-02-01 2025-04-30 0001676047 us-gaap:CommonStockMember 2025-04-30 0001676047 us-gaap:AdditionalPaidInCapitalMember 2025-04-30 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-30 0001676047 us-gaap:RetainedEarningsMember 2025-04-30 0001676047 us-gaap:TreasuryStockCommonMember 2025-04-30 0001676047 2024-01-31 0001676047 us-gaap:CommonStockMember 2024-01-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2024-01-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-31 0001676047 us-gaap:RetainedEarningsMember 2024-01-31 0001676047 us-gaap:TreasuryStockCommonMember 2024-01-31 0001676047 us-gaap:CommonStockMember 2024-02-01 2024-04-30 0001676047 us-gaap:AdditionalPaidInCapitalMember 2024-02-01 2024-04-30 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-02-01 2024-04-30 0001676047 us-gaap:RetainedEarningsMember 2024-02-01 2024-04-30 0001676047 us-gaap:TreasuryStockCommonMember 2024-02-01 2024-04-30 0001676047 2024-04-30 0001676047 us-gaap:CommonStockMember 2024-04-30 0001676047 us-gaap:AdditionalPaidInCapitalMember 2024-04-30 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-30 0001676047 us-gaap:RetainedEarningsMember 2024-04-30 0001676047 us-gaap:TreasuryStockCommonMember 2024-04-30 0001676047 ntrb:FourPTherapeuticsLLCMember 2018-08-01 0001676047 ntrb:FourPTherapeuticsLLCMember us-gaap:CommonStockMember 2018-08-01 2018-08-01 0001676047 ntrb:FourPTherapeuticsLLCMember us-gaap:CommonStockMember 2018-08-01 0001676047 2018-08-01 0001676047 ntrb:PoconoPharmaceuticalsMember 2020-08-31 0001676047 ntrb:CreditLineNoteFacilityMember us-gaap:RelatedPartyMember 2023-03-31 0001676047 ntrb:CreditLineNoteFacilityMember us-gaap:RelatedPartyMember 2023-07-13 0001676047 ntrb:CreditLineNoteFacilityMember 2024-04-19 2024-04-19 0001676047 ntrb:LoanMember 2025-02-01 2025-04-30 0001676047 srt:MinimumMember 2025-04-30 0001676047 srt:MaximumMember 2025-04-30 0001676047 us-gaap:IntellectualPropertyMember 2024-04-01 2025-01-31 0001676047 ntrb:FourPTherapeuticsLLCMember 2025-04-30 0001676047 ntrb:PoconoCoatedProductsLLCAndActiveIntelligenceLLCMember 2020-08-31 0001676047 2024-02-01 2025-01-31 0001676047 2023-02-01 2024-01-31 0001676047 ntrb:ActiveIntelligenceLLCMember 2025-02-01 2025-04-30 0001676047 2025-04-30 2025-04-30 0001676047 2024-04-30 2024-04-30 0001676047 ntrb:SaleOfGoodsMember 2025-02-01 2025-04-30 0001676047 ntrb:SaleOfGoodsMember 2024-02-01 2024-04-30 0001676047 us-gaap:ServiceMember 2025-02-01 2025-04-30 0001676047 us-gaap:ServiceMember 2024-02-01 2024-04-30 0001676047 country:US 2025-02-01 2025-04-30 0001676047 country:US 2024-02-01 2024-04-30 0001676047 ntrb:ForeignMember 2025-02-01 2025-04-30 0001676047 ntrb:ForeignMember 2024-02-01 2024-04-30 0001676047 srt:MinimumMember us-gaap:EquipmentMember 2025-04-30 0001676047 srt:MaximumMember us-gaap:EquipmentMember 2025-04-30 0001676047 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2025-04-30 0001676047 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2025-04-30 0001676047 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2025-04-30 0001676047 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2025-04-30 0001676047 us-gaap:CostOfSalesMember 2025-02-01 2025-04-30 0001676047 us-gaap:CostOfSalesMember 2024-02-01 2024-04-30 0001676047 us-gaap:EquipmentMember 2025-04-30 0001676047 us-gaap:EquipmentMember 2025-01-31 0001676047 us-gaap:MachineryAndEquipmentMember 2025-04-30 0001676047 us-gaap:MachineryAndEquipmentMember 2025-01-31 0001676047 us-gaap:FurnitureAndFixturesMember 2025-04-30 0001676047 us-gaap:FurnitureAndFixturesMember 2025-01-31 0001676047 us-gaap:LineOfCreditMember 2025-04-30 0001676047 us-gaap:LineOfCreditMember 2025-02-01 2025-04-30 0001676047 us-gaap:LineOfCreditMember 2025-01-31 0001676047 ntrb:AutomobileMember 2022-04-03 0001676047 ntrb:AutomobileMember 2022-04-03 2022-04-03 0001676047 ntrb:AutomobileMember 2025-04-30 0001676047 ntrb:AutomobileMember 2025-01-31 0001676047 ntrb:NotePayableRelatedPartyMember 2023-07-17 0001676047 ntrb:NotePayableRelatedPartyMember 2025-04-30 0001676047 ntrb:NotePayableRelatedPartyMember 2024-02-01 2024-10-31 0001676047 ntrb:NotePayableRelatedPartyMember 2024-05-15 0001676047 ntrb:NotePayableRelatedPartyMember 2025-02-01 2025-04-30 0001676047 ntrb:NotePayableRelatedPartyMember 2025-01-31 0001676047 ntrb:NotePayableRelatedPartyMember 2024-02-01 2024-04-30 0001676047 ntrb:SecuredBorrowingLiabilityMember 2023-07-19 0001676047 ntrb:SecuredBorrowingLiabilityMember 2025-02-01 2025-04-30 0001676047 ntrb:SecuredBorrowingLiabilityMember 2024-02-01 2024-04-30 0001676047 us-gaap:IntellectualPropertyMember 2024-02-01 2025-01-31 0001676047 ntrb:CustomerBaseMember 2025-04-30 0001676047 ntrb:CustomerBaseMember 2025-01-31 0001676047 us-gaap:IntellectualPropertyMember 2025-04-30 0001676047 us-gaap:IntellectualPropertyMember 2025-01-31 0001676047 us-gaap:CommonStockMember 2024-03-31 2024-03-31 0001676047 srt:ChiefExecutiveOfficerMember 2024-03-31 0001676047 ntrb:EmployeeMember 2024-03-31 0001676047 2024-03-31 2024-03-31 0001676047 us-gaap:CommonStockMember 2024-04-19 2024-04-19 0001676047 2024-04-19 2024-04-19 0001676047 2024-04-19 0001676047 us-gaap:CommonStockMember 2024-04-19 0001676047 srt:ChiefFinancialOfficerMember us-gaap:CommonStockMember 2024-04-19 2024-04-19 0001676047 us-gaap:RelatedPartyMember us-gaap:CommonStockMember 2024-04-19 2024-04-19 0001676047 ntrb:TIIJetServicesLDAMember 2024-02-01 2024-04-30 0001676047 2016-01-15 0001676047 us-gaap:SeriesAPreferredStockMember 2019-05-24 0001676047 us-gaap:SeriesAPreferredStockMember 2019-06-20 0001676047 us-gaap:CommonStockMember 2022-07-26 2022-07-26 0001676047 srt:MinimumMember 2022-08-04 0001676047 srt:MaximumMember 2022-08-04 0001676047 us-gaap:TreasuryStockCommonMember 2025-03-04 0001676047 ntrb:ConsultantMember us-gaap:CommonStockMember 2025-02-01 2025-04-30 0001676047 us-gaap:WarrantMember 2025-02-28 0001676047 us-gaap:WarrantMember us-gaap:CommonStockMember 2025-02-28 2025-02-28 0001676047 us-gaap:IPOMember 2024-04-19 2024-04-19 0001676047 us-gaap:WarrantMember 2024-04-19 2024-04-19 0001676047 us-gaap:WarrantMember 2024-04-19 0001676047 us-gaap:WarrantMember ntrb:BarandnicHoldingsLtdMember 2024-04-19 0001676047 us-gaap:WarrantMember 2024-05-15 0001676047 us-gaap:WarrantMember 2024-05-15 2024-05-15 0001676047 us-gaap:WarrantMember ntrb:BarandnicHoldingsLtdMember 2024-05-15 0001676047 srt:ChiefFinancialOfficerMember us-gaap:WarrantMember 2024-06-05 0001676047 us-gaap:CommonStockMember 2024-06-05 2024-06-05 0001676047 us-gaap:WarrantMember 2024-09-10 0001676047 us-gaap:WarrantMember 2024-02-01 2025-01-31 0001676047 srt:MaximumMember us-gaap:WarrantMember 2025-02-01 2025-04-30 0001676047 us-gaap:WarrantMember 2025-02-01 2025-04-30 0001676047 srt:MinimumMember us-gaap:WarrantMember 2025-02-01 2025-04-30 0001676047 us-gaap:EmployeeStockOptionMember 2021-11-01 0001676047 us-gaap:EmployeeStockOptionMember 2022-02-01 2022-02-01 0001676047 us-gaap:EmployeeStockOptionMember 2023-02-01 2023-02-01 0001676047 us-gaap:EmployeeStockOptionMember 2021-11-03 0001676047 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2024-03-20 0001676047 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2024-03-20 0001676047 us-gaap:EmployeeStockOptionMember 2025-02-01 0001676047 us-gaap:EmployeeStockOptionMember 2024-02-01 2025-01-31 0001676047 srt:MinimumMember srt:ChiefExecutiveOfficerMember 2024-02-01 2025-01-31 0001676047 srt:MaximumMember srt:ChiefExecutiveOfficerMember 2024-02-01 2025-01-31 0001676047 srt:ChiefExecutiveOfficerMember us-gaap:EmployeeStockOptionMember 2025-01-31 0001676047 srt:MinimumMember 2024-02-01 2025-01-31 0001676047 srt:MaximumMember 2024-02-01 2025-01-31 0001676047 us-gaap:WarrantMember 2024-01-31 0001676047 us-gaap:WarrantMember 2024-01-31 2024-01-31 0001676047 us-gaap:WarrantMember 2024-02-01 2024-04-30 0001676047 us-gaap:WarrantMember 2024-04-30 0001676047 us-gaap:WarrantMember 2025-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesTwoMember 2025-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesTwoMember 2025-02-01 2025-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesThreeMember 2025-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesThreeMember 2025-02-01 2025-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesFourMember 2025-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesFourMember 2025-02-01 2025-04-30 0001676047 2024-01-31 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesOneMember 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesOneMember 2025-02-01 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwoMember 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwoMember 2025-02-01 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThreeMember 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThreeMember 2025-02-01 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFourMember 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFourMember 2025-02-01 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFiveMember 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFiveMember 2025-02-01 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSixMember 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSixMember 2025-02-01 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSevenMember 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSevenMember 2025-02-01 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesEightMember 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesEightMember 2025-02-01 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesNineMember 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesNineMember 2025-02-01 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTenMember 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTenMember 2025-02-01 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesElevenMember 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesElevenMember 2025-02-01 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwelveMember 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwelveMember 2025-02-01 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThirteenMember 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThirteenMember 2025-02-01 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFourteenMember 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFourteenMember 2025-02-01 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFifteenMember 2025-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFifteenMember 2025-02-01 2025-04-30 0001676047 us-gaap:StockOptionMember 2025-04-30 0001676047 us-gaap:StockOptionMember 2025-02-01 2025-04-30 0001676047 ntrb:PoconoPharmaceuticalsMember 2025-02-01 2025-04-30 0001676047 ntrb:PoconoPharmaceuticalsMember 2024-02-01 2024-04-30 0001676047 ntrb:FourPTherapeuticsMember 2025-02-01 2025-04-30 0001676047 ntrb:FourPTherapeuticsMember 2024-02-01 2024-04-30 0001676047 ntrb:SellingGeneralAndAdministrativePoconoPharmaceuticalsMember 2025-02-01 2025-04-30 0001676047 ntrb:SellingGeneralAndAdministrativePoconoPharmaceuticalsMember 2024-02-01 2024-04-30 0001676047 ntrb:SellingGeneralAndAdministrative4PTherapeuticsMember 2025-02-01 2025-04-30 0001676047 ntrb:SellingGeneralAndAdministrative4PTherapeuticsMember 2024-02-01 2024-04-30 0001676047 ntrb:SellingGeneralAndAdministrativeCorporateMember 2025-02-01 2025-04-30 0001676047 ntrb:SellingGeneralAndAdministrativeCorporateMember 2024-02-01 2024-04-30 0001676047 ntrb:ResearchAndDevelopment4PTherapeuticsMember 2025-02-01 2025-04-30 0001676047 ntrb:ResearchAndDevelopment4PTherapeuticsMember 2024-02-01 2024-04-30 0001676047 us-gaap:CorporateAndOtherMember 2025-02-01 2025-04-30 0001676047 us-gaap:CorporateAndOtherMember 2024-02-01 2024-04-30 0001676047 us-gaap:NonUsMember 2025-02-01 2025-04-30 0001676047 us-gaap:NonUsMember 2024-02-01 2024-04-30 0001676047 country:US 2025-04-30 0001676047 country:US 2025-01-31 0001676047 us-gaap:NonUsMember 2025-04-30 0001676047 us-gaap:NonUsMember 2025-01-31 0001676047 us-gaap:CorporateAndOtherMember 2025-04-30 0001676047 us-gaap:CorporateAndOtherMember 2025-01-31 0001676047 ntrb:PoconoPharmaceuticalsMember 2025-04-30 0001676047 ntrb:PoconoPharmaceuticalsMember 2025-01-31 0001676047 ntrb:FourPTherapeuticsMember 2025-04-30 0001676047 ntrb:FourPTherapeuticsMember 2025-01-31 0001676047 2022-07-31 0001676047 srt:ChiefExecutiveOfficerMember 2025-04-30 0001676047 ntrb:MrGoodmanMember 2022-07-31 0001676047 2025-01-31 2025-01-31 0001676047 2022-02-01 0001676047 2022-02-01 2022-02-01 0001676047 2023-07-25 2023-07-25 0001676047 2023-07-25 0001676047 ntrb:SorrentoTherapeuticsIncMember 2023-07-25 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure utr:sqft

Filing Compare · NutriBand Inc.